<?xml version="1.0" encoding="UTF-8"?><full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1413867025000200</prism:url><dc:identifier>doi:10.1016/j.bjid.2025.104517</dc:identifier><eid>1-s2.0-S1413867025000200</eid><prism:doi>10.1016/j.bjid.2025.104517</prism:doi><pii>S1413-8670(25)00020-0</pii><dc:title>Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease </dc:title><prism:publicationName>The Brazilian Journal of Infectious Diseases</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><pubType>fla</pubType><prism:issn>14138670</prism:issn><prism:volume>29</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>104517</prism:startingPage><prism:pageRange>104517</prism:pageRange><prism:number>2</prism:number><articleNumber>104517</articleNumber><dc:format>application/xml</dc:format><prism:coverDate>2025-04-30</prism:coverDate><prism:coverDisplayDate>March–April 2025</prism:coverDisplayDate><prism:copyright>© 2025 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U.</prism:copyright><prism:publisher>Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U.</prism:publisher><dc:creator>Cortés, Jorge Alberto</dc:creator><dc:creator>Rodríguez-Lugo, Diego Andrés</dc:creator><dc:creator>Valderrama-Rios, Martha Carolina</dc:creator><dc:creator>Rabagliati, Ricardo</dc:creator><dc:creator>Capone, Domenico</dc:creator><dc:creator>Álvarez-Moreno, Carlos Arturo</dc:creator><dc:creator>Varón-Vega, Fabio</dc:creator><dc:creator>Nocua-Báez, Laura Cristina</dc:creator><dc:creator>Diaz-Brochero, Cándida</dc:creator><dc:creator>Enciso Olivera, Leonardo</dc:creator><dc:creator>Cuervo-Maldonado, Sonia Isabel</dc:creator><dc:creator>Thompson, Luis</dc:creator><dc:creator>Corzo-León, Dora E.</dc:creator><dc:creator>Cuéllar, Luis E.</dc:creator><dc:creator>Vergara, Erika Paola</dc:creator><dc:creator>Riera, Fernando</dc:creator><dc:creator>Cornejo-Juárez, Patricia</dc:creator><dc:creator>Rojas, Rita</dc:creator><dc:creator>Gómez, Beatriz L.</dc:creator><dc:creator>Celis-Ramírez, Adriana Marcela</dc:creator><dc:creator>Sandoval-Gutiérrez, José Luis</dc:creator><dc:creator>Sarmiento, Mauricio</dc:creator><dc:creator>Ochoa, Diana Lorena</dc:creator><dc:creator>Nucci, Marcio</dc:creator><dc:description>
                  Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
               </dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType>Author</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by/4.0/</openaccessUserLicense><dcterms:subject>Invasive pulmonary aspergillosis</dcterms:subject><dcterms:subject>Hematologic neoplasms</dcterms:subject><dcterms:subject>Antifungal agents</dcterms:subject><dcterms:subject>Latin America</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S1413867025000200" rel="self"/><link href="https://www.sciencedirect.com/science/article/pii/S1413867025000200" rel="scidir"/></coredata><objects><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="389" height="811" size="43405">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="527" height="719" size="51389">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="472" size="30986">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="621" height="763" size="47992">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="78" height="163" size="5244">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="120" height="164" size="6663">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="164" size="6710">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="133" height="164" size="5555">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1725" height="3596" size="387754">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2333" height="3182" size="483709">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2667" height="2091" size="254175">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2750" height="3381" size="405410">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="32043">https://api.elsevier.com/content/object/eid/1-s2.0-S1413867025000200-mmc1.docx?httpAccept=%2A%2F%2A</object></objects><scopus-id>85218442830</scopus-id><scopus-eid>2-s2.0-85218442830</scopus-eid><pubmed-id>39999620</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85218442830" rel="abstract"/><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>280278</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291889</xocs:ssid>
         <xocs:ssid type="subj">291903</xocs:ssid>
         <xocs:ssid type="subj">291904</xocs:ssid>
         <xocs:ssid type="subj">291910</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
         <xocs:ssid type="oa">90</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>The Brazilian Journal of Infectious Diseases</xocs:srctitle>
      <xocs:normalized-srctitle>BRAZILIANJOURNALINFECTIOUSDISEASES</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20250224">2025-02-24</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20250224">2025-02-24</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20250224">2025-02-24</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20250224">2025-02-24</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2025-03-27T10:56:44</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1413867025000200</xocs:eid>
      <xocs:pii-formatted>S1413-8670(25)00020-0</xocs:pii-formatted>
      <xocs:pii-unformatted>S1413867025000200</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.bjid.2025.104517</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1413867025X00027</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20250327">2025-03-27T12:15:54.939775Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20250301</xocs:date-search-begin>
      <xocs:date-search-end>20250430</xocs:date-search-end>
      <xocs:year-nav>2025</xocs:year-nav>
      <xocs:indexeddate epoch="1740395075">2025-02-24T11:04:35.096259Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast orcid primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1413-8670</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>14138670</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
      <xocs:funding-body-id>NONE</xocs:funding-body-id>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>29</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>29</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>2</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>2</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 29, Issue 2</xocs:vol-iss-suppl-text>
      <xocs:sort-order>9</xocs:sort-order>
      <xocs:first-fp>104517</xocs:first-fp>
      <xocs:article-number>104517</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>104517</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202503</xocs:start-date>
         <xocs:end-date>202504</xocs:end-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>March–April 2025</xocs:cover-date-text>
      <xocs:cover-date-start>2025-03-01</xocs:cover-date-start>
      <xocs:cover-date-end>2025-04-30</xocs:cover-date-end>
      <xocs:cover-date-year>2025</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original Articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2025 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U.</xocs:copyright-line>
      <xocs:normalized-article-title>EVIDENCEBASEDCLINICALSTANDARDFORDIAGNOSISTREATMENTINVASIVELUNGASPERGILLOSISINPATIENTONCOHEMATOLOGICDISEASE</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>CORTES</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>J</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Scope</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Target</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Patients considered and clinical aspects addressed</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Patients not considered and clinical issues not addressed</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Users to whom the clinical practice guide is directed and healthcare field</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Methods</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>EBCS development group composition</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Definition of scope and objective</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Systematic search of CPG</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Screening, quality assessment, and selection of CPGs</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Preparation of proposed recommendations and preliminary algorithm</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Expert consensus</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Results</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Flowchart</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Implementation of EBCS</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>EBCS update</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Ethical considerations</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Funding source</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Editorial independence</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Authors’ contribution</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary materials</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0001">
            <xocs:ref-normalized-surname>CADENA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>125</xocs:ref-first-fp>
            <xocs:ref-last-lp>142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0002">
            <xocs:ref-normalized-surname>PAGANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>i5</xocs:ref-first-fp>
            <xocs:ref-last-lp>14</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0003">
            <xocs:ref-normalized-surname>THOMPSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>1496</xocs:ref-first-fp>
            <xocs:ref-last-lp>1509</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0004">
            <xocs:ref-normalized-surname>ULLMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>335</xocs:ref-first-fp>
            <xocs:ref-last-lp>347</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>CORNELY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>348</xocs:ref-first-fp>
            <xocs:ref-last-lp>359</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0006">
            <xocs:ref-normalized-surname>RIVASPINEDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2022</xocs:ref-pub-year>
            <xocs:ref-first-fp>262</xocs:ref-first-fp>
            <xocs:ref-last-lp>296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0007">
            <xocs:ref-normalized-surname>RABAGLIATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>212</xocs:ref-first-fp>
            <xocs:ref-last-lp>219</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0008">
            <xocs:ref-normalized-surname>AQUINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>277</xocs:ref-first-fp>
            <xocs:ref-last-lp>280</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0009">
            <xocs:ref-normalized-surname>SIFUENTESOSORNIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>23</xocs:ref-first-fp>
            <xocs:ref-last-lp>34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>GOYENECHEGARCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>1092</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0011">
            <xocs:ref-normalized-surname>DENNING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2022</xocs:ref-pub-year>
            <xocs:ref-first-fp>109</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0012">
            <xocs:ref-normalized-surname>MACEDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>93</xocs:ref-first-fp>
            <xocs:ref-last-lp>103</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>LATINAMERICA</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>EMERGENCETRIAZOLERESISTANCEINASPERGILLUSSPP</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0013">
            <xocs:ref-normalized-surname>ALVAREZMORENO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>45631</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0014">
            <xocs:ref-pub-year>2022</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>DEVELOPMENTPUBLICHEALTHACTION</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>COLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>e412</xocs:ref-first-fp>
            <xocs:ref-last-lp>e419</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0016">
            <xocs:ref-normalized-surname>FALCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>368</xocs:ref-first-fp>
            <xocs:ref-last-lp>373</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0017">
            <xocs:ref-normalized-surname>ORTIZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2024</xocs:ref-pub-year>
            <xocs:ref-first-fp>ofae578</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0018">
            <xocs:ref-normalized-surname>SANJUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>452</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0019"/>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>GUIAMETODOLOGICAPARALAELABORACIONDEGUIASDEPRACTICACLINICACONEVALUACIONECONOMICAENELSISTEMAGENERALDESEGURIDADSOCIALENSALUDCOLOMBIANO</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0021">
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>GUIAMETODOLOGICAADOPCIONADAPTACIONDEGUIASDEPRACTICACLINICABASADASENEVIDENCIA</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0022">
            <xocs:ref-normalized-surname>BROUWERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>E839</xocs:ref-first-fp>
            <xocs:ref-last-lp>E842</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0023">
            <xocs:ref-normalized-surname>PATTERSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>e1</xocs:ref-first-fp>
            <xocs:ref-last-lp>e60</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0024">
            <xocs:ref-normalized-surname>TEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>67</xocs:ref-first-fp>
            <xocs:ref-last-lp>88</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>DOUGLAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>143</xocs:ref-first-fp>
            <xocs:ref-last-lp>176</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0026">
            <xocs:ref-normalized-surname>ONATE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2022</xocs:ref-pub-year>
            <xocs:ref-first-fp>297</xocs:ref-first-fp>
            <xocs:ref-last-lp>339</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0027">
            <xocs:ref-normalized-surname>GUTIERREZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>GUIAMETODOLOGICAPARALAELABORACIONDEGUIASDEPRACTICACLINICACONEVALUACIONECONOMICAENELSISTEMAGENERALDESEGURIDADSOCIALENSALUDCOLOMBIANOBOGOTADC</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0028">
            <xocs:ref-normalized-surname>ANDREWS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>719</xocs:ref-first-fp>
            <xocs:ref-last-lp>725</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0029">
            <xocs:ref-normalized-surname>PEDRAZASANCHEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>777</xocs:ref-first-fp>
            <xocs:ref-last-lp>785</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>MATTIUZZI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>450</xocs:ref-first-fp>
            <xocs:ref-last-lp>456</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0031">
            <xocs:ref-normalized-surname>FISHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>864</xocs:ref-first-fp>
            <xocs:ref-last-lp>871</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0032">
            <xocs:ref-normalized-surname>CALMETTES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>26724</xocs:ref-first-fp>
            <xocs:ref-last-lp>26736</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0033">
            <xocs:ref-normalized-surname>GIRMENIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>667</xocs:ref-first-fp>
            <xocs:ref-last-lp>674</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0034">
            <xocs:ref-normalized-surname>NUCCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-article-number>e2021025</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>STANZANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>610</xocs:ref-first-fp>
            <xocs:ref-last-lp>616</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0036">
            <xocs:ref-normalized-surname>HENZLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4483</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0037">
            <xocs:ref-normalized-surname>STANZANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>371</xocs:ref-first-fp>
            <xocs:ref-last-lp>380</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0038">
            <xocs:ref-normalized-surname>MERCIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>S89</xocs:ref-first-fp>
            <xocs:ref-last-lp>S94</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0039">
            <xocs:ref-normalized-surname>AQUINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>191</xocs:ref-first-fp>
            <xocs:ref-last-lp>202</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>DURAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>i1</xocs:ref-first-fp>
            <xocs:ref-last-lp>i44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0041">
            <xocs:ref-normalized-surname>MOHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>S37</xocs:ref-first-fp>
            <xocs:ref-last-lp>S89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0042">
            <xocs:ref-normalized-surname>SANGOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>364</xocs:ref-first-fp>
            <xocs:ref-last-lp>375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0043">
            <xocs:ref-normalized-surname>POWERSFLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2655</xocs:ref-first-fp>
            <xocs:ref-last-lp>2660</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0044">
            <xocs:ref-normalized-surname>KIDD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2903</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>ARVANITIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>490</xocs:ref-first-fp>
            <xocs:ref-last-lp>526</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0046">
            <xocs:ref-normalized-surname>CHAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>37</xocs:ref-first-fp>
            <xocs:ref-last-lp>66</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0047">
            <xocs:ref-normalized-surname>PERSONETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>8629891</xocs:ref-article-number>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0048">
            <xocs:ref-normalized-surname>ALVAREZLERMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>360</xocs:ref-first-fp>
            <xocs:ref-last-lp>368</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0049">
            <xocs:ref-normalized-surname>OBATA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>279</xocs:ref-first-fp>
            <xocs:ref-last-lp>287</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>RAAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>283</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0051">
            <xocs:ref-normalized-surname>ARUANNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0052">
            <xocs:ref-normalized-surname>AZANZA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2023</xocs:ref-pub-year>
            <xocs:ref-first-fp>236</xocs:ref-first-fp>
            <xocs:ref-last-lp>258</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0053">
            <xocs:ref-normalized-surname>ASHBEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1162</xocs:ref-first-fp>
            <xocs:ref-last-lp>1176</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>CORTESX2025X104517</xocs:refkey3>
         <xocs:refkey4ai>CORTESX2025X104517XJ</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status>
         <xocs:oa-access-effective-date>2025-02-06T14:55:37Z</xocs:oa-access-effective-date>
         <xocs:oa-sponsor>
            <xocs:oa-sponsor-type>Author</xocs:oa-sponsor-type>
         </xocs:oa-sponsor>
         <xocs:oa-user-license>http://creativecommons.org/licenses/by/4.0/</xocs:oa-user-license>
      </xocs:open-access>
      <xocs:copyright-info>
         <xocs:cp-license-lines>
            <xocs:cp-license-line lang="en">This is an open access article under the CC BY license.</xocs:cp-license-line>
         </xocs:cp-license-lines>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2025 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2025-02-24T12:19:19.757Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-matched-string>School of Medicine of the Universidad Nacional de Colombia</xocs:funding-agency-matched-string>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency>Pfizer</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100004319</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding-text>This document has been developed as part of the \u201CAntifungal administration programs in a Latin American country\u201D project of the Universidad Nacional de Colombia, financed by a grant from Pfizer Inc. The project's objectives included developing recommendations for diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease in Latin America. In addition, the publication was supported by the School of Medicine of the Universidad Nacional de Colombia, through funding for the edition of the manuscript in English. </xocs:funding-text>
      </xocs:funding-list>
      <xocs:article-sharing-framework/>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1413-8670(25)00020-0</xocs:pii-formatted>
         <xocs:pii-unformatted>S1413867025000200</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1413867025000200</xocs:eid>
         <xocs:doi>10.1016/j.bjid.2025.104517</xocs:doi>
         <xocs:cid>280278</xocs:cid>
         <xocs:timestamp>2025-03-27T12:15:54.939775Z</xocs:timestamp>
         <xocs:cover-date-start>2025-03-01</xocs:cover-date-start>
         <xocs:cover-date-end>2025-04-30</xocs:cover-date-end>
         <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
         <xocs:funding-body-id>NONE</xocs:funding-body-id>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/MAIN/application/pdf/20043e5eba1b53133c9799dc0ecb988e/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2298724</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1413867025000200-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/PREVIEW/image/png/5efbf847cc41534072b0cc6a3aabfc36/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>52409</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/gr3/DOWNSAMPLED/image/jpeg/01052c9f68810fbe87b7cee0985e4518/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43405</xocs:filesize>
               <xocs:pixel-height>811</xocs:pixel-height>
               <xocs:pixel-width>389</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/gr4/DOWNSAMPLED/image/jpeg/859691a050fa44aed01f0a6d830881fa/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>51389</xocs:filesize>
               <xocs:pixel-height>719</xocs:pixel-height>
               <xocs:pixel-width>527</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/gr1/DOWNSAMPLED/image/jpeg/e8376a6510ed7b341e390064b67b60ff/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30986</xocs:filesize>
               <xocs:pixel-height>472</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/gr2/DOWNSAMPLED/image/jpeg/ecffea1771abd18ad4d6acc9350cf0bb/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>47992</xocs:filesize>
               <xocs:pixel-height>763</xocs:pixel-height>
               <xocs:pixel-width>621</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/gr3/THUMBNAIL/image/gif/2e0caf4518ea9fb9f6f8f7d350e6d82a/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5244</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>78</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/gr4/THUMBNAIL/image/gif/da1dda2b6516cbed248c452052d24bc5/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6663</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>120</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/gr1/THUMBNAIL/image/gif/149304167fbf324753f51f30e2ba79d5/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6710</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/gr2/THUMBNAIL/image/gif/06f28a4423e720e840f31a60bca29f51/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5555</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>133</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/HIGHRES/image/jpeg/76fbc82ffa2c086dc686c5675392b2f2/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>387754</xocs:filesize>
               <xocs:pixel-height>3596</xocs:pixel-height>
               <xocs:pixel-width>1725</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/HIGHRES/image/jpeg/18f749260d728f0a6338211917f93b6b/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>483709</xocs:filesize>
               <xocs:pixel-height>3182</xocs:pixel-height>
               <xocs:pixel-width>2333</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/HIGHRES/image/jpeg/d3823dd39bfae6c2560cb69d92f9f522/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>254175</xocs:filesize>
               <xocs:pixel-height>2091</xocs:pixel-height>
               <xocs:pixel-width>2667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000169/HIGHRES/image/jpeg/35e2c7372ab501ff6575340f6e3edb48/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>405410</xocs:filesize>
               <xocs:pixel-height>3381</xocs:pixel-height>
               <xocs:pixel-width>2750</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1413867025000200-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1413867025000200/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/4008d116921feddd73686534a630ea0f/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>32043</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" xml:lang="en" version="5.7">
         <item-info>
            <jid>BJID</jid>
            <aid>104517</aid>
            <ce:article-number>104517</ce:article-number>
            <ce:pii>S1413-8670(25)00020-0</ce:pii>
            <ce:doi>10.1016/j.bjid.2025.104517</ce:doi>
            <ce:copyright type="society" year="2025">Sociedade Brasileira de Infectologia</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0001">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0001">
                  <ce:simple-para id="spara001" view="all">Flowchart for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease. ICD-10, International Classification of Diseases, 10th revision.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0001" role="short">Fig. 1</ce:alt-text>
               <ce:link id="celink0001" locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S1413867025000200/gr1"/>
            </ce:figure>
            <ce:figure id="fig0002">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0002">
                  <ce:simple-para id="spara002" view="all">Flowchart Section 1: Primary antifungal prophylaxis of the patient with oncohematologic disease at high-risk of invasive lung aspergillosis.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0002" role="short">Fig. 2</ce:alt-text>
               <ce:link id="celink0002" locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S1413867025000200/gr2"/>
            </ce:figure>
            <ce:figure id="fig0003">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0003">
                  <ce:simple-para id="spara003" view="all">Section 2 of the flowchart: Diagnosis of the patient with oncohematologic disease with clinical suspicion of invasive lung aspergillosis. CT, Computed Tomography; BAL, Bronchoalveolar Lavage; ICD-10, International Classification of Diseases, 10th revision.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0003" role="short">Fig. 3</ce:alt-text>
               <ce:link id="celink0003" locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S1413867025000200/gr3"/>
            </ce:figure>
            <ce:figure id="fig0004">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0004">
                  <ce:simple-para id="spara004" view="all">Section 3 of the flowchart: Treatment of the patient with oncohematologic disease diagnosed with invasive lung aspergillosis. ICD-10, International Classification of Diseases, 10th revision.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0004" role="short">Fig. 4</ce:alt-text>
               <ce:link id="celink0004" locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S1413867025000200/gr4"/>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0001" rowsep="0" colsep="0" frame="topbot">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spara005" view="all">Overall grading of evidence using the GRADE system.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0005" role="short">Table 1</ce:alt-text>
               <tgroup cols="2">
                  <colspec colnum="1" colname="col1" align="left"/>
                  <colspec colnum="2" colname="col2" align="left"/>
                  <thead>
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0001" align="left" valign="top" rowsep="1" role="colgroup" namest="col1" nameend="col2">
                           <bold>Levels of certainty of evidence</bold>
                           <cross-ref id="crf0162" refid="bib0027">
                              <sup loc="post">27</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0002" colname="col1" valign="top">High</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0003" colname="col2" valign="top">There is high confidence that the true effect is close to the effect estimate.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0004" colname="col1" valign="top">Moderate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0005" colname="col2" valign="top">The confidence in the effect estimate is moderate. The true effect may be close to the estimate, but it could be substantially different.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0006" colname="col1" valign="top">Download</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0007" colname="col2" valign="top">Confidence in the effect estimate is limited. The true effect may be substantially different from the effect estimate.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0008" colname="col1" valign="top">Very low</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0009" colname="col2" valign="top">The confidence in the effect estimate is very low. The true effect is likely to be substantially different from the effect estimate.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0010" align="left" valign="top" role="colgroup" namest="col1" nameend="col2">
                           <bold>Meaning of the strength and direction of the recommendations</bold>
                           <cross-ref id="crf0163" refid="bib0027">
                              <sup loc="post">27</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0011" colname="col1" valign="top">Strongly in favor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0012" colname="col2" valign="top">The benefits of the intervention clearly outweigh the undesirable effects.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0013" colname="col1" valign="top">Conditionally in favor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0014" colname="col2" valign="top">The benefits of the intervention probably outweigh the undesirable effects.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0015" colname="col1" valign="top">Strongly against</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0016" colname="col2" valign="top">The undesirable effects of the intervention clearly outweigh the benefits.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0017" colname="col1" valign="top">Conditionally against</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0018" colname="col2" valign="top">The undesirable effects of the intervention probably outweigh the benefits.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0019" align="left" valign="top" role="colgroup" namest="col1" nameend="col2">Implications of the strength of the recommendation<cross-ref id="crf0164" refid="bib0028">
                              <sup loc="post">28</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0020" align="left" valign="top" role="colgroup" namest="col1" nameend="col2">
                           <bold>The implications of a strong recommendation are</bold>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0021" colname="col1" valign="top">For patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0022" colname="col2" valign="top">Most people in this situation would desire the recommended course of action, and only a small proportion would not.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0023" colname="col1" valign="top">For clinicians</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0024" colname="col2" valign="top">Most patients should receive the recommended course of action.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0025" colname="col1" valign="top">For policy makers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0026" colname="col2" valign="top">The recommendation can be adopted as a policy in most situations.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0027" align="left" valign="top" role="colgroup" namest="col1" nameend="col2">
                           <bold>The implications of a conditional recommendation are</bold>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0028" colname="col1" valign="top">For patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0029" colname="col2" valign="top">Most people in this situation would like the recommended course of action, but many do not.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0030" colname="col1" valign="top">For clinicians</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0031" colname="col2" valign="top">You should recognize that different options will be appropriate for different patients, and you should help each patient arrive at a management decision consistent with his or her values and preferences.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0032" colname="col1" valign="top">For policy makers</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0033" colname="col2" valign="top">Policy formulation will require substantial debate and the involvement of many stakeholders.</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0002" rowsep="0" colsep="0" frame="topbot">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0006">
                  <ce:simple-para id="spara006" view="all">Primary antifungal prophylaxis of the patient with oncohematological disease at high-risk of invasive lung aspergillosis.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0006" role="short">Table 2</ce:alt-text>
               <tgroup cols="2">
                  <colspec colnum="1" colname="col1" align="left"/>
                  <colspec colnum="2" colname="col2" align="left"/>
                  <thead>
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0034" colname="col1" valign="top">
                           <bold>Antifungal</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0035" colname="col2" valign="top">
                           <bold>Dosage</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0036" colname="col1" morerows="1" align="left" valign="top" role="rowgroup">Posaconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0037" colname="col2" valign="top">Tablet: 300 mg every 12 h on the 1st day and then 300 mg everyday PO</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0039" colname="col2" valign="top">Solution: 200 mg every 8 h PO</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0040" colname="col1" valign="top">Voriconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0041" colname="col2" valign="top">4 mg/kg every 12 h PO or IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0042" colname="col1" valign="top">Caspofungin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0043" colname="col2" valign="top">70 mg on the 1st day then 50 mg every day IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0044" colname="col1" valign="top">Micafungin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0045" colname="col2" valign="top">100–150 mg every day IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0046" colname="col1" valign="top">Liposomal amphotericin B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0047" colname="col2" valign="top">3 mg/kg 3-times a week IV</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara007" view="all">PO, Per Oral; IV, Intravenous.</ce:simple-para>
                  <ce:simple-para id="spara008" view="all">Taken and adapted from.<ce:cross-ref id="crf0165" refid="bib0023">
                        <ce:sup loc="post">23</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0166" refid="bib0024">
                        <ce:sup loc="post">24</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0167" refid="bib0030">
                        <ce:sup loc="post">30</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0003" rowsep="0" colsep="0" frame="topbot">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0007">
                  <ce:simple-para id="spara009" view="all">Antifungal treatment of patients with oncohematologic disease diagnosed with invasive lung aspergillosis.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0007" role="short">Table 3</ce:alt-text>
               <tgroup cols="2">
                  <colspec colnum="1" colname="col1" align="left"/>
                  <colspec colnum="2" colname="col2" align="left"/>
                  <thead>
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0048" colname="col1" valign="top">
                           <bold>Antifungal</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0049" colname="col2" valign="top">
                           <bold>Dosage</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0050" colname="col1" morerows="1" align="left" valign="top" role="rowgroup">Voriconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0051" colname="col2" valign="top">6 mg/kg every 12 h on the 1st day then continue with 4 mg/kg every 12 h IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0053" colname="col2" valign="top">4 mg/kg every 12 h PO</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0054" colname="col1" valign="top">Isavuconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0055" colname="col2" valign="top">200 mg every 8 h for 2 days and then continue 200 mg everyday PO or IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0056" colname="col1" morerows="1" align="left" valign="top" role="rowgroup">Posaconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0057" colname="col2" valign="top">300 mg every 12 h on the 1st day then continue with 300 mg everyday Tablet PO or IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0059" colname="col2" valign="top">400 mg every 12 h or 200 mg every 6 h PO Suspension</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0060" colname="col1" valign="top">Liposomal amphotericin B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0061" colname="col2" valign="top">3 mg/kg everyday IV</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0062" colname="col1" valign="top">Amphotericin B lipid complex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0063" colname="col2" valign="top">5 mg/kg everyday IV</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara010" view="all">PO, Per Oral; IV, Intravenous.</ce:simple-para>
                  <ce:simple-para id="spara011" view="all">Taken and adapted from.<ce:cross-ref id="crf0168" refid="bib0023">
                        <ce:sup loc="post">23</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0169" refid="bib0025">
                        <ce:sup loc="post">25</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0004" rowsep="0" colsep="0" frame="topbot">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0008">
                  <ce:simple-para id="spara012" view="all">Main drug interactions to consider in patients with oncohematologic disease under treatment for invasive lung aspergillosis with extended-spectrum azoles.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0008" role="short">Table 4</ce:alt-text>
               <tgroup cols="3">
                  <colspec colnum="1" colname="col1" align="left"/>
                  <colspec colnum="2" colname="col2" align="left"/>
                  <colspec colnum="3" colname="col3" align="left"/>
                  <thead>
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0064" colname="col1" valign="top">
                           <bold>Azol</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0065" colname="col2" valign="top">
                           <bold>Effect on metabolic enzymes and transport proteins</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0066" colname="col3" valign="top">
                           <bold>Chemotherapeutic agent with interaction</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0067" colname="col1" valign="top">Voriconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0068" colname="col2" valign="top">Mild inhibitor of CYP2C19, moderate inhibitor of CYP2C9, and strong inhibitor of CYP3A4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0069" colname="col3" valign="top">Holo-transretinoic acid, axitinib, cyclosporine, ibrutinib, midostaurin, ruxolitinib, arsenic trioxide</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0070" colname="col1" valign="top">Isavuconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0071" colname="col2" valign="top">Moderate inhibitor of CYP3A4/5, and mild inhibitor of gp-P, OCT2 and UGT. Mild CYP2B6 inducer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0072" colname="col3" valign="top">Bosutinib, cyclophosphamide, venetoclax</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0073" colname="col1" valign="top">Posaconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0074" colname="col2" valign="top">Potent inhibitor of CYP3A4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0075" colname="col3" valign="top">Acalabrutinib, all-trans retinoic acid, bosutinib, cyclophosphamide, cyclosporine, dasatinib, midostaurin, ruxolitinib, venetoclax</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara013" view="all">CYP, Cytochrome P450; gp-P, P-glycoprotein; OCT2, Organic Cation Transporter 2; UGT, Uridine Diphosphate Glucuronyltransferase.</ce:simple-para>
                  <ce:simple-para id="spara014" view="all">Taken and adapted from.<ce:cross-ref id="crf0170" refid="bib0046">
                        <ce:sup loc="post">46</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0171" refid="bib0052">
                        <ce:sup loc="post">52</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" rowsep="0" colsep="0" frame="topbot">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0009">
                  <ce:simple-para id="spara015" view="all">Measurement of serum concentrations of voriconazole or posaconazole in the patient with oncohematologic disease under treatment for invasive lung aspergillosis.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0009" role="short">Table 5</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1" align="left"/>
                  <colspec colnum="2" colname="col2" align="left"/>
                  <colspec colnum="3" colname="col3" align="left"/>
                  <colspec colnum="4" colname="col4" align="left"/>
                  <thead>
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0076" colname="col1" align="left" valign="top">
                           <bold>Antifungal</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0077" colname="col2" align="left" valign="top">
                           <bold>Moment of measurement</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0078" colname="col3" valign="top">
                           <bold>Therapeutic goal</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0079" colname="col4" align="left" valign="top">
                           <bold>Toxicity</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0080" colname="col1" morerows="1" align="left" valign="top" role="rowgroup">Voriconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0081" colname="col2" morerows="1" align="left" valign="top" role="rowgroup">Between the 4th and 7th day of starting treatment or the 4th day after an adjustment is made</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0082" colname="col3" valign="top">Prophylaxis: &gt; 1 mg/dL.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0083" colname="col4" morerows="1" align="left" valign="top" role="rowgroup">Maintain &lt; 5–6 mg/dL to reduce risk</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0086" colname="col3" valign="top">Treatment: 1–5.5 mg/dL or Cmin/MIC 2–5</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0088" colname="col1" morerows="1" align="left" valign="top" role="rowgroup">Posaconazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0089" colname="col2" morerows="1" align="left" valign="top" role="rowgroup">Between the 4th and 7th day of starting treatment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0090" colname="col3" valign="top">Prophylaxis: &gt; 0.7 mg/dL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0091" colname="col4" morerows="1" align="left" valign="top" role="rowgroup">Maintain &lt; 3.75 mg/dL to reduce risk</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0094" colname="col3" valign="top">Treatment: &gt; 1 mg/dL</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara016" view="all">Cmin, Minimum Concentration/valley; MIC, Minimum Inhibitory Concentration.</ce:simple-para>
                  <ce:simple-para id="spara017" view="all">Taken and adapted from.<ce:cross-ref id="crf0172" refid="bib0023">
                        <ce:sup loc="post">23</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0173" refid="bib0026">
                        <ce:sup loc="post">26</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0174" refid="bib0053">
                        <ce:sup loc="post">53</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0006" rowsep="0" colsep="0" frame="topbot">
               <ce:label>Table 6</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spara018" view="all">Indicators for the implementation of EBCS.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alt0010" role="short">Table 6</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1" align="left"/>
                  <colspec colnum="2" colname="col2" align="left"/>
                  <colspec colnum="3" colname="col3" align="left"/>
                  <colspec colnum="4" colname="col4" align="left"/>
                  <thead>
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0096" colname="col1" valign="top">
                           <bold>Name</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0097" colname="col2" valign="top">
                           <bold>Definition</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0098" colname="col3" valign="top">
                           <bold>Numerator</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0099" colname="col4" valign="top">
                           <bold>Denominator</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0100" colname="col1" valign="top">1. Use of posaconazole as primary antifungal prophylaxis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0101" colname="col2" valign="top">Proportion of adult patients with oncohematologic disease and high risk of invasive aspergillosis<cross-ref id="crf0175" refid="tb6fn1">
                              <sup loc="post">a</sup>
                           </cross-ref>, using posaconazole as primary antifungal prophylaxis.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0102" colname="col3" valign="top">Total number of adult patients with oncohematologic disease and high risk of invasive aspergillosis<cross-ref id="crf0176" refid="tb6fn1">
                              <sup loc="post">a</sup>
                           </cross-ref>, without contraindication to the use of azoles, with use of posaconazole as primary antifungal prophylaxis.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0103" colname="col4" valign="top">Total number of adult patients with oncohematologic disease and high risk of invasive aspergillosis<cross-ref id="crf0177" refid="tb6fn1">
                              <sup loc="post">a</sup>
                           </cross-ref>, without contraindication to the use of azoles.</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0104" colname="col1" valign="top">2. High-resolution / thin-slice chest CT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0105" colname="col2" valign="top">Proportion of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, with high-resolution / thin-section chest CT.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0106" colname="col3" valign="top">Total number of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, with high-resolution / thin-slice chest CT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0107" colname="col4" valign="top">Total number of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0108" colname="col1" valign="top">3. Bronchoscopy with BAL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0109" colname="col2" valign="top">Proportion of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, with bronchoscopy with BAL performed.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0110" colname="col3" valign="top">Total number of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, without contraindication to perform BAL, with bronchoscopy with BAL.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0111" colname="col4" valign="top">Total number of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, without contraindication to perform BAL</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0112" colname="col1" valign="top">4. Direct microscopic examination and mycological culture</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0113" colname="col2" valign="top">Proportion of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, with direct microscopic examination and mycological culture of respiratory tract samples (induced sputum, tracheal aspirates, BAL).</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0114" colname="col3" valign="top">Total number of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected, with direct microscopic examination and mycological culture of respiratory tract samples (induced sputum, tracheal aspirates, BAL).</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0115" colname="col4" valign="top">Total number of adult patients with oncohematologic disease diagnosis and invasive lung aspergillosis suspected</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0116" colname="col1" valign="top">5. Use of an extended-spectrum azole as initial antifungal therapy.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0117" colname="col2" valign="top">Proportion of adult patients with oncohematologic disease, without previous antifungal prophylaxis against filamentous fungi, and diagnosed with invasive lung aspergillosis, using an extended-spectrum azole (voriconazole, isavuconazole, or posaconazole) as initial antifungal therapy.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0118" colname="col3" valign="top">Total number of adult patients with oncohematologic disease, without previous antifungal prophylaxis against filamentous fungi, and diagnosed with invasive lung aspergillosis, without contraindication for the use of azoles, with use of an extended-spectrum azole (voriconazole, isavuconazole or posaconazole) as initial antifungal therapy.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" id="en0119" colname="col4" valign="top">Total number of adult patients with oncohematologic disease, without previous antifungal prophylaxis against filamentous fungi, and diagnosed with invasive lung aspergillosis, without contraindication for the use of azoles.</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tb6fn1">
                  <ce:label>a</ce:label>
                  <ce:note-para id="notep0009" view="all">Patients with severe graft-versus-host disease or acute myeloid leukemia or myelodysplastic syndrome on induction with intensive chemotherapy.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dchd0001">
               <ce:textfn id="dhtxt0001">Original Article</ce:textfn>
            </ce:dochead>
            <ce:title id="tte0002">Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease</ce:title>
            <ce:author-group id="aut0001">
               <ce:author id="au0001" author-id="S1413867025000200-b5d7cd4f74d16f2eefbcd5415bf47409" orcid="0000-0002-0882-9652">
                  <ce:given-name>Jorge Alberto</ce:given-name>
                  <ce:surname>Cortés</ce:surname>
                  <ce:cross-ref id="crf0001" refid="aff0001">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0002" refid="aff0002">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0003" refid="cor0001">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au0002" author-id="S1413867025000200-a8e9b9e257c6a338de7b81b01a33acc8" orcid="0000-0002-4251-7871">
                  <ce:given-name>Diego Andrés</ce:given-name>
                  <ce:surname>Rodríguez-Lugo</ce:surname>
                  <ce:cross-ref id="crf0004" refid="aff0001">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0003" author-id="S1413867025000200-d7e53da492bbb13fe6609f91d49c240c">
                  <ce:given-name>Martha Carolina</ce:given-name>
                  <ce:surname>Valderrama-Rios</ce:surname>
                  <ce:cross-ref id="crf0005" refid="aff0001">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0006" refid="aff0002">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0004" author-id="S1413867025000200-8fe8de25a42880130cc612a79ce03c95" orcid="0000-0002-0574-8312">
                  <ce:given-name>Ricardo</ce:given-name>
                  <ce:surname>Rabagliati</ce:surname>
                  <ce:cross-ref id="crf0007" refid="aff0003">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0005" author-id="S1413867025000200-c5d128904a04e3cdf716eb45b1599c6d" orcid="0000-0002-3966-0052">
                  <ce:given-name>Domenico</ce:given-name>
                  <ce:surname>Capone</ce:surname>
                  <ce:cross-ref id="crf0008" refid="aff0004">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0009" refid="aff0005">
                     <ce:sup loc="post">e</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0006" author-id="S1413867025000200-95a75ca5c10c2c45c01e22fca5dd8b5d" orcid="0000-0001-5419-4494">
                  <ce:given-name>Carlos Arturo</ce:given-name>
                  <ce:surname>Álvarez-Moreno</ce:surname>
                  <ce:cross-ref id="crf0010" refid="aff0001">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0011" refid="aff0006">
                     <ce:sup loc="post">f</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0007" author-id="S1413867025000200-e9b805bbc7dc2fb3b60bad9d07756214" orcid="0000-0002-4000-6007">
                  <ce:given-name>Fabio</ce:given-name>
                  <ce:surname>Varón-Vega</ce:surname>
                  <ce:cross-ref id="crf0012" refid="aff0007">
                     <ce:sup loc="post">g</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0008" author-id="S1413867025000200-14d15e4cf6ebbdd059d0ada109e57bb3" orcid="0000-0003-2869-2339">
                  <ce:given-name>Laura Cristina</ce:given-name>
                  <ce:surname>Nocua-Báez</ce:surname>
                  <ce:cross-ref id="crf0013" refid="aff0001">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0009" author-id="S1413867025000200-7cd288bbbc2db646b1ae5ccc06a47805" orcid="0000-0002-2176-7388">
                  <ce:given-name>Cándida</ce:given-name>
                  <ce:surname>Diaz-Brochero</ce:surname>
                  <ce:cross-ref id="crf0014" refid="aff0008">
                     <ce:sup loc="post">h</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0010" author-id="S1413867025000200-74523ef7b2b821de3ae3fbdb385cde3c" orcid="0000-0001-5540-1969">
                  <ce:given-name>Leonardo</ce:given-name>
                  <ce:surname>Enciso Olivera</ce:surname>
                  <ce:cross-ref id="crf0015" refid="aff0009">
                     <ce:sup loc="post">i</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0011" author-id="S1413867025000200-a2f8408eef6d03348f3910154dd87631">
                  <ce:given-name>Sonia Isabel</ce:given-name>
                  <ce:surname>Cuervo-Maldonado</ce:surname>
                  <ce:cross-ref id="crf0016" refid="aff0001">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0017" refid="aff0010">
                     <ce:sup loc="post">j</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0012" author-id="S1413867025000200-8f0baa9ba35b0a32146929f8ac683e19">
                  <ce:given-name>Luis</ce:given-name>
                  <ce:surname>Thompson</ce:surname>
                  <ce:cross-ref id="crf0018" refid="aff0011">
                     <ce:sup loc="post">k</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0013" author-id="S1413867025000200-b2192d14f01abd19247954baf3429132">
                  <ce:given-name>Dora E.</ce:given-name>
                  <ce:surname>Corzo-León</ce:surname>
                  <ce:cross-ref id="crf0019" refid="aff0012">
                     <ce:sup loc="post">l</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0014" author-id="S1413867025000200-f747a3d6252d1481400c7564c68c9658">
                  <ce:given-name>Luis E.</ce:given-name>
                  <ce:surname>Cuéllar</ce:surname>
                  <ce:cross-ref id="crf0020" refid="aff0013">
                     <ce:sup loc="post">m</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0021" refid="aff0014">
                     <ce:sup loc="post">n</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0015" author-id="S1413867025000200-e5a9d4a7e12277ab8ae67b9fa7aa865d">
                  <ce:given-name>Erika Paola</ce:given-name>
                  <ce:surname>Vergara</ce:surname>
                  <ce:cross-ref id="crf0022" refid="aff0002">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0023" refid="aff0015">
                     <ce:sup loc="post">o</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0016" author-id="S1413867025000200-66ca02d453c7055335adf59486cf2602">
                  <ce:given-name>Fernando</ce:given-name>
                  <ce:surname>Riera</ce:surname>
                  <ce:cross-ref id="crf0024" refid="aff0016">
                     <ce:sup loc="post">p</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0025" refid="aff0017">
                     <ce:sup loc="post">q</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0017" author-id="S1413867025000200-71548156cebcb91c83fa41e0b4a9d0d7">
                  <ce:given-name>Patricia</ce:given-name>
                  <ce:surname>Cornejo-Juárez</ce:surname>
                  <ce:cross-ref id="crf0026" refid="aff0018">
                     <ce:sup loc="post">r</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0018" author-id="S1413867025000200-05ff5310a11ecbbd8daaeb243e907f5e">
                  <ce:given-name>Rita</ce:given-name>
                  <ce:surname>Rojas</ce:surname>
                  <ce:cross-ref id="crf0027" refid="aff0019">
                     <ce:sup loc="post">s</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0019" author-id="S1413867025000200-d612bfd0345c66a564b77556122502f9">
                  <ce:given-name>Beatriz L.</ce:given-name>
                  <ce:surname>Gómez</ce:surname>
                  <ce:cross-ref id="crf0028" refid="aff0020">
                     <ce:sup loc="post">t</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0020" author-id="S1413867025000200-9fcc70b3e2c9310010d113d81c09c656">
                  <ce:given-name>Adriana Marcela</ce:given-name>
                  <ce:surname>Celis-Ramírez</ce:surname>
                  <ce:cross-ref id="crf0029" refid="aff0021">
                     <ce:sup loc="post">u</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0030" refid="aff0022">
                     <ce:sup loc="post">v</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0021" author-id="S1413867025000200-6555d67dacb0f8b204b60700a05688c2">
                  <ce:given-name>José Luis</ce:given-name>
                  <ce:surname>Sandoval-Gutiérrez</ce:surname>
                  <ce:cross-ref id="crf0031" refid="aff0023">
                     <ce:sup loc="post">w</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0022" author-id="S1413867025000200-ff29fd5368dce93aa63f102e30721256">
                  <ce:given-name>Mauricio</ce:given-name>
                  <ce:surname>Sarmiento</ce:surname>
                  <ce:cross-ref id="crf0032" refid="aff0024">
                     <ce:sup loc="post">x</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0023" author-id="S1413867025000200-d2ba2091bda97f43f3dd260a670fe79f">
                  <ce:given-name>Diana Lorena</ce:given-name>
                  <ce:surname>Ochoa</ce:surname>
                  <ce:cross-ref id="crf0033" refid="aff0025">
                     <ce:sup loc="post">y</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au0024" author-id="S1413867025000200-d0169a0d86a86e77c36d6f1175462a53">
                  <ce:given-name>Marcio</ce:given-name>
                  <ce:surname>Nucci</ce:surname>
                  <ce:cross-ref id="crf0034" refid="aff0026">
                     <ce:sup loc="post">z</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0035" refid="aff0027">
                     <ce:sup loc="post">aa</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:affiliation id="aff0001" affiliation-id="S1413867025000200-3ca12e3e129044e6cfffc575c4b374f1">
                  <ce:label>a</ce:label>
                  <ce:textfn id="cetextfn0001">Universidad Nacional de Colombia, Facultad de Medicina, Departamento de Medicina Interna, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Universidad Nacional de Colombia</sa:organization>
                     <sa:organization>Facultad de Medicina, Departamento de Medicina Interna</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0001">aUniversidad Nacional de Colombia, Facultad de Medicina, Departamento de Medicina Interna, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0002" affiliation-id="S1413867025000200-05204b45849019f5871109401cdbb159">
                  <ce:label>b</ce:label>
                  <ce:textfn id="cetextfn0002">Hospital Universitario Nacional de Colombia, Unidad de Infectología, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Hospital Universitario Nacional de Colombia</sa:organization>
                     <sa:organization>Unidad de Infectología</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0002">bHospital Universitario Nacional de Colombia, Unidad de Infectología, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0003" affiliation-id="S1413867025000200-e9a09708bfd64d0b0b278aa7ca215811">
                  <ce:label>c</ce:label>
                  <ce:textfn id="cetextfn0003">Pontificia Universidad Católica de Chile, Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Santiago, Chile</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Pontificia Universidad Católica de Chile</sa:organization>
                     <sa:organization>Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto</sa:organization>
                     <sa:city>Santiago</sa:city>
                     <sa:country iso3166-1-alpha-3="CHL">Chile</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0003">cPontificia Universidad Católica de Chile, Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Santiago, Chile</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0004" affiliation-id="S1413867025000200-6987fb385fba6c658c0c56c208a1d24f">
                  <ce:label>d</ce:label>
                  <ce:textfn id="cetextfn0004">Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro (UFRJ)</sa:organization>
                     <sa:city>Rio de Janeiro</sa:city>
                     <sa:state>RJ</sa:state>
                     <sa:country iso3166-1-alpha-3="BRA">Brazil</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0004">dInstituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0005" affiliation-id="S1413867025000200-0da2dedb5972517583314105ea098965">
                  <ce:label>e</ce:label>
                  <ce:textfn id="cetextfn0005">Disciplina de Pneumologia da Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Disciplina de Pneumologia da Universidade do Estado do Rio de Janeiro (UERJ)</sa:organization>
                     <sa:city>Rio de Janeiro</sa:city>
                     <sa:state>RJ</sa:state>
                     <sa:country iso3166-1-alpha-3="BRA">Brazil</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0005">eDisciplina de Pneumologia da Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0006" affiliation-id="S1413867025000200-b2fd39d02ce4dd90c5491b1956113fc1">
                  <ce:label>f</ce:label>
                  <ce:textfn id="cetextfn0006">Clínica Universitaria Colombia, Clínica Colsanitas Grupo Keralty, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Clínica Universitaria Colombia</sa:organization>
                     <sa:organization>Clínica Colsanitas Grupo Keralty</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0006">fClínica Universitaria Colombia, Clínica Colsanitas Grupo Keralty, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0007" affiliation-id="S1413867025000200-bcc61b04322e0793307681e78664f520">
                  <ce:label>g</ce:label>
                  <ce:textfn id="cetextfn0007">Medicina Interna-Neumología-Cuidado Intensivo, Unidad de Cuidado Intensivo Médica, Fundación Neumológica Colombiana, Fundación Cardioinfantil, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Medicina Interna-Neumología-Cuidado Intensivo, Unidad de Cuidado Intensivo Médica</sa:organization>
                     <sa:organization>Fundación Neumológica Colombiana, Fundación Cardioinfantil</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0007">gMedicina Interna-Neumología-Cuidado Intensivo, Unidad de Cuidado Intensivo Médica, Fundación Neumológica Colombiana, Fundación Cardioinfantil, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0008" affiliation-id="S1413867025000200-e1414935d8d4f687d3cdeebcf90308a2">
                  <ce:label>h</ce:label>
                  <ce:textfn id="cetextfn0008">Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Departamento de Medicina Interna, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Pontificia Universidad Javeriana, Hospital Universitario San Ignacio</sa:organization>
                     <sa:organization>Departamento de Medicina Interna</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0008">hPontificia Universidad Javeriana, Hospital Universitario San Ignacio, Departamento de Medicina Interna, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0009" affiliation-id="S1413867025000200-e7fa849fe5e31b50ede0daa393d9c7d8">
                  <ce:label>i</ce:label>
                  <ce:textfn id="cetextfn0009">Hospital Universitario Nacional de Colombia, Unidad de Hematología, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Hospital Universitario Nacional de Colombia</sa:organization>
                     <sa:organization>Unidad de Hematología</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0009">iHospital Universitario Nacional de Colombia, Unidad de Hematología, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0010" affiliation-id="S1413867025000200-3bffffd392abf33aed1050b2c5523ac1">
                  <ce:label>j</ce:label>
                  <ce:textfn id="cetextfn0010">Instituto Nacional de Cancerología, Grupo Infectología, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Instituto Nacional de Cancerología</sa:organization>
                     <sa:organization>Grupo Infectología</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0010">jInstituto Nacional de Cancerología, Grupo Infectología, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0011" affiliation-id="S1413867025000200-7fc136864489fdd9f2d769f464c812d7">
                  <ce:label>k</ce:label>
                  <ce:textfn id="cetextfn0011">Unidad de Infectología, Clínica Alemana ‒ Universidad del Desarrollo, Departamento de Medicina Interna, Santiago, Chile</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Unidad de Infectología, Clínica Alemana ‒ Universidad del Desarrollo</sa:organization>
                     <sa:organization>Departamento de Medicina Interna</sa:organization>
                     <sa:city>Santiago</sa:city>
                     <sa:country iso3166-1-alpha-3="CHL">Chile</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0011">kUnidad de Infectología, Clínica Alemana ‒ Universidad del Desarrollo, Departamento de Medicina Interna, Santiago, Chile</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0012" affiliation-id="S1413867025000200-7d8d4d9bf857c8adda659a388037a3d7">
                  <ce:label>l</ce:label>
                  <ce:textfn id="cetextfn0012">Universidad de Exeter, Centro de Micología Médica Del Medical Research Council, Exeter, United Kingdom</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Universidad de Exeter</sa:organization>
                     <sa:organization>Centro de Micología Médica Del Medical Research Council</sa:organization>
                     <sa:city>Exeter</sa:city>
                     <sa:country iso3166-1-alpha-3="GBR">United Kingdom</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0012">lUniversidad de Exeter, Centro de Micología Médica Del Medical Research Council, Exeter, , Reino Unido</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0013" affiliation-id="S1413867025000200-0ca6c04d2294c87f08d3186ee22f58c4">
                  <ce:label>m</ce:label>
                  <ce:textfn id="cetextfn0013">Instituto Nacional de Enfermedades Neoplásicas, Unidad de Infectología, Lima, Perú</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Instituto Nacional de Enfermedades Neoplásicas</sa:organization>
                     <sa:organization>Unidad de Infectología</sa:organization>
                     <sa:city>Lima</sa:city>
                     <sa:country iso3166-1-alpha-3="PER">Perú</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0013">mInstituto Nacional de Enfermedades Neoplásicas, Unidad de Infectología, Lima, Perú</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0014" affiliation-id="S1413867025000200-476a290bef83365cb9bfd1521f2b3c23">
                  <ce:label>n</ce:label>
                  <ce:textfn id="cetextfn0014">Universidad Nacional Federico Villarreal, Lima, Perú</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Universidad Nacional Federico Villarreal</sa:organization>
                     <sa:city>Lima</sa:city>
                     <sa:country iso3166-1-alpha-3="PER">Perú</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0014">nUniversidad Nacional Federico Villarreal, Lima, Perú</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0015" affiliation-id="S1413867025000200-621b65df88b3c4f90a495783b84bfb52">
                  <ce:label>o</ce:label>
                  <ce:textfn id="cetextfn0015">Hospital Infantil Universitario de San José, Departamento de Infectología, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Hospital Infantil Universitario de San José</sa:organization>
                     <sa:organization>Departamento de Infectología</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0015">oHospital Infantil Universitario de San José, Departamento de Infectología, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0016" affiliation-id="S1413867025000200-9a19b53b084cd636da628cb70707f91f">
                  <ce:label>p</ce:label>
                  <ce:textfn id="cetextfn0016">División de Enfermedades Infecciosas, Sanatorio Allende Córdoba, Córdoba, Argentina</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>División de Enfermedades Infecciosas</sa:organization>
                     <sa:organization>Sanatorio Allende Córdoba</sa:organization>
                     <sa:city>Córdoba</sa:city>
                     <sa:country iso3166-1-alpha-3="ARG">Argentina</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0016">pDivisión de Enfermedades Infecciosas, Sanatorio Allende Córdoba, Córdoba, Argentina</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0017" affiliation-id="S1413867025000200-2eace5de8ff769668a39fbba48934d1d">
                  <ce:label>q</ce:label>
                  <ce:textfn id="cetextfn0017">Enfermedades Infecciosas, Universidad Nacional de Córdoba, Córdoba, Argentina</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Enfermedades Infecciosas</sa:organization>
                     <sa:organization>Universidad Nacional de Córdoba</sa:organization>
                     <sa:city>Córdoba</sa:city>
                     <sa:country iso3166-1-alpha-3="ARG">Argentina</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0017">qEnfermedades Infecciosas, Universidad Nacional de Córdoba, Córdoba, Argentina</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0018" affiliation-id="S1413867025000200-d9267a86e4fc4d932a8e37e694fd7f42">
                  <ce:label>r</ce:label>
                  <ce:textfn id="cetextfn0018">Instituto Nacional de Cancerología, Departamento de Infectología, Ciudad de México, México</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Instituto Nacional de Cancerología</sa:organization>
                     <sa:organization>Departamento de Infectología</sa:organization>
                     <sa:city>Ciudad de México</sa:city>
                     <sa:country iso3166-1-alpha-3="MEX">México</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0018">rInstituto Nacional de Cancerología, Departamento de Infectología, Ciudad de México, Mexico</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0019" affiliation-id="S1413867025000200-dfc2d7eb40f5e902d78a43f2de6431d6">
                  <ce:label>s</ce:label>
                  <ce:textfn id="cetextfn0019">Hospital General Plaza de la Salud, Santo Domingo, República Dominicana</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Hospital General Plaza de la Salud</sa:organization>
                     <sa:city>Santo Domingo</sa:city>
                     <sa:state>República Dominicana</sa:state>
                  </sa:affiliation>
                  <ce:source-text id="staff0019">sHospital General Plaza de la Salud, Santo Domingo, República Dominicana</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0020" affiliation-id="S1413867025000200-ceaf289ff52b4694ae5bfe0f48a5c6fe">
                  <ce:label>t</ce:label>
                  <ce:textfn id="cetextfn0020">Grupo de Estudios en Microbiología Traslacional y Enfermedades Emergentes (MICROS), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Grupo de Estudios en Microbiología Traslacional y Enfermedades Emergentes (MICROS)</sa:organization>
                     <sa:organization>Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0020">tGrupo de Estudios en Microbiología Traslacional y Enfermedades Emergentes (MICROS), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0021" affiliation-id="S1413867025000200-5dba5757e79296c55ed0427f9e239b71">
                  <ce:label>u</ce:label>
                  <ce:textfn id="cetextfn0021">Grupo de Investigación Celular y Molecular de Microorganismos Patógenos (CeMoP), Departamento de Ciencias Biológicas, Universidad de los Andes, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Grupo de Investigación Celular y Molecular de Microorganismos Patógenos (CeMoP)</sa:organization>
                     <sa:organization>Departamento de Ciencias Biológicas, Universidad de los Andes</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0021">uGrupo de Investigación Celular y Molecular de Microorganismos Patógenos (CeMoP), Departamento de Ciencias Biológicas, Universidad de los Andes, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0022" affiliation-id="S1413867025000200-0b4384798a93390790eab5e0b5027148">
                  <ce:label>v</ce:label>
                  <ce:textfn id="cetextfn0022">Laboratorio de Investigación Celular y Molecular de Patógenos (CeMoP), Departamento de Ciencias Biológicas, Universidad de los Andes, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Laboratorio de Investigación Celular y Molecular de Patógenos (CeMoP)</sa:organization>
                     <sa:organization>Departamento de Ciencias Biológicas, Universidad de los Andes</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0022">vLaboratorio de Investigación Celular y Molecular de Patógenos (CeMoP), Departamento de Ciencias Biológicas, Universidad de los Andes, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0023" affiliation-id="S1413867025000200-d375bfe0014e016920795d78f066fb97">
                  <ce:label>w</ce:label>
                  <ce:textfn id="cetextfn0023">Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, México</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Instituto Nacional de Enfermedades Respiratorias</sa:organization>
                     <sa:city>Ciudad de México</sa:city>
                     <sa:country iso3166-1-alpha-3="MEX">México</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0023">wInstituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0024" affiliation-id="S1413867025000200-66c435d7ee244abd916ff4e80663ca4b">
                  <ce:label>x</ce:label>
                  <ce:textfn id="cetextfn0024">Departamento de Hematología y Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Departamento de Hematología y Oncología, Escuela de Medicina</sa:organization>
                     <sa:organization>Pontificia Universidad Católica de Chile</sa:organization>
                     <sa:city>Santiago</sa:city>
                     <sa:country iso3166-1-alpha-3="CHL">Chile</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0024">xDepartamento de Hematología y Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0025" affiliation-id="S1413867025000200-010ebb130cf30f8fbe62aafd902b5a80">
                  <ce:label>y</ce:label>
                  <ce:textfn id="cetextfn0025">Departamento de Radiología e Imágenes Diagnosticas, Hospital Universitário Nacional de Colombia, Bogotá, Colombia</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Departamento de Radiología e Imágenes Diagnosticas</sa:organization>
                     <sa:organization>Hospital Universitário Nacional de Colombia</sa:organization>
                     <sa:city>Bogotá</sa:city>
                     <sa:country iso3166-1-alpha-3="COL">Colombia</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0025">yDepartamento de Radiología e Imágenes Diagnosticas, Hospital Universitário Nacional de Colombia, Bogotá, Colombia</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0026" affiliation-id="S1413867025000200-2affa6a5da3562fbaa729230d38820a4">
                  <ce:label>z</ce:label>
                  <ce:textfn id="cetextfn0026">Departament of Internal Medicine, Hospital Universitario, Universidade Federal do Rio de Janeiro, Río de Janeiro, RJ, Brazil</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Departament of Internal Medicine</sa:organization>
                     <sa:organization>Hospital Universitario, Universidade Federal do Rio de Janeiro</sa:organization>
                     <sa:city>Río de Janeiro</sa:city>
                     <sa:state>RJ</sa:state>
                     <sa:country iso3166-1-alpha-3="BRA">Brazil</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0026">zDepartamento de Medicina Interna, Hospital Universitario, Universidada Federal de Rio de Janeiro, Río de Janeiro, RJ, Brazil</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0027" affiliation-id="S1413867025000200-1a448a150c8fd8b9aafb3e6d82cef82c">
                  <ce:label>aa</ce:label>
                  <ce:textfn id="cetextfn0027">Grupo Oncoclínicas, Brazil</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Grupo Oncoclínicas</sa:organization>
                     <sa:country iso3166-1-alpha-3="BRA">Brazil</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="staff0027">aaGrupo Oncoclínicas, Brazil</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor0001">
                  <ce:label>⁎</ce:label>
                  <ce:text id="cetext0001">Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="12" month="8" year="2024"/>
            <ce:date-accepted day="16" month="1" year="2025"/>
            <ce:abstract id="abs0001" class="author" view="all"><ce:abstract-sec id="abss0001" view="all">
                  <ce:simple-para id="spara019" view="all">Aspergillosis is a disease caused by the filamentous fungus <ce:italic>Aspergillus</ce:italic> spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put <ce:italic>Aspergilus</ce:italic> spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:keywords id="keys0001" class="keyword" view="all">
               <ce:section-title id="cesectitle0002">Keywords</ce:section-title>
               <ce:keyword id="key0001">
                  <ce:text id="cetext0002">Invasive pulmonary aspergillosis</ce:text>
               </ce:keyword>
               <ce:keyword id="key0002">
                  <ce:text id="cetext0003">Hematologic neoplasms</ce:text>
               </ce:keyword>
               <ce:keyword id="key0003">
                  <ce:text id="cetext0004">Antifungal agents</ce:text>
               </ce:keyword>
               <ce:keyword id="key0004">
                  <ce:text id="cetext0005">Latin America</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0001" role="introduction" view="all">
                  <ce:section-title id="cesectitle0003">Introduction</ce:section-title>
                  <ce:para id="para0001" view="all">The invasive aspergillosis typically affects immunocompromised patients and is one of the leading causes of death from infections in patients with oncohematologic pathologies. The main <ce:italic>Aspergillus</ce:italic> species that cause this disease are <ce:italic>A. fumigatus, A. flavus, A. terreus</ce:italic>, and A<ce:italic>. niger</ce:italic>.<ce:cross-ref id="crf0036" refid="bib0001">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0037" refid="bib0002">
                        <ce:sup loc="post">2</ce:sup>
                     </ce:cross-ref> The number of aspergillosis cases increases every year, which has been attributed to the growing number of immunocompromised individuals, optimization in diagnosis, improved cancer treatments, and the development of new immunosuppressive drugs.<ce:cross-ref id="crf0038" refid="bib0003">
                        <ce:sup loc="post">3</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para0002" view="all">Several oncohematological pathologies carry a high-risk of aspergillosis, equal to or higher than 10 %, including acute myeloid leukemia, myelodysplastic syndrome (in induction therapy), and allogeneic hematopoietic stem cell transplantation, especially when associated with graft-versus-host disease.<ce:cross-ref id="crf0039" refid="bib0004">
                        <ce:sup loc="post">4</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0040" refid="bib0005">
                        <ce:sup loc="post">5</ce:sup>
                     </ce:cross-ref> Although with data that may vary between centers, in general, autologous hematopoietic stem cell transplant recipients, patients with acute lymphoid leukemia, and those with Hodgkin's or nonHodgkin's lymphomas are considered to be associated with a low risk of aspergillosis,<ce:cross-ref id="crf0041" refid="bib0001">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0042" refid="bib0006">
                        <ce:sup loc="post">6</ce:sup>
                     </ce:cross-ref> although, of course, this risk can vary depending on factors like pathology, chemotherapy regimen, hospital care setting, and timing of patient evaluation.</ce:para>
                  <ce:para id="para0003" view="all">Globally, it is estimated that &gt;300,000 cases occur per year, with mortality data in some registries exceeding 90 %. <ce:italic>Aspergillus</ce:italic> spp. is the main cause of invasive fungal disease in patients with allogeneic hematopoietic stem cell transplantation in Latin America, making up 63.4 % of reported cases in the region,<ce:cross-ref id="crf0043" refid="bib0007">
                        <ce:sup loc="post">7</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0044" refid="bib0008">
                        <ce:sup loc="post">8</ce:sup>
                     </ce:cross-ref> with two peak times of presentation, within the first 30-days and after 90-days posttransplant, affecting 3 % of patients with this type of transplantation, the most associated species being <ce:italic>A. fumigatus</ce:italic> and the main organ involved being the lung.<ce:cross-ref id="crf0045" refid="bib0009">
                        <ce:sup loc="post">9</ce:sup>
                     </ce:cross-ref>
                     <ce:sup loc="post">,</ce:sup>
                     <ce:cross-ref id="crf0046" refid="bib0010">
                        <ce:sup loc="post">10</ce:sup>
                     </ce:cross-ref> In addition to the constant increase in cases of this entity, an increasing number of cases with identification of azole-resistant <ce:italic>A. fumigatus</ce:italic> has also been observed, which are associated with a mortality 20 %‒30 % higher than in cases of infection by sensitive strains<ce:cross-refs id="crf0047" refid="bib0011 bib0012 bib0013">
                        <ce:sup loc="post">11–13</ce:sup>
                     </ce:cross-refs> with reported mortality rates ranging from 47 % to 100 %. In 2022, the World Health Organization (WHO) classified <ce:italic>A. fumigatus</ce:italic> as a critical priority pathogen to guide research, development, and public health actions.<ce:cross-ref id="crf0049" refid="bib0014">
                        <ce:sup loc="post">14</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para0004" view="all">Restricted access to advanced diagnostic tools is one of the reasons why invasive aspergillosis, among other fungal infections, is underdiagnosed in low- and middle-income countries,<ce:cross-ref id="crf0050" refid="bib0015">
                        <ce:sup loc="post">15</ce:sup>
                     </ce:cross-ref> Latin America is a clear example of this. Falci and Pasqualotto, in a study conducted in several countries in the region found that, in 107 laboratories evaluated, galactomannan was available in only 48 %, with even more worrisome deficiencies for Polymerase Chain Reaction (PCR), which was found in only 20 % of 73 institutions with access to molecular testing. In this same study, regarding the availability of antifungals evaluated in 124 centers, access to liposomal amphotericin B and voriconazole was found in only 49 % and 55 %, respectively.<ce:cross-ref id="crf0051" refid="bib0016">
                        <ce:sup loc="post">16</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para0005" view="all">Ortiz et al., in a study done in 2023, evaluated the diagnostic and therapeutic capabilities for the management of invasive fungal infections in Honduras through a survey of microbiologists and clinicians, finding that only 2.6 % of the institutions evaluated had antigen detection available for Aspergillus spp. infections and that PCR was not available in any center. In addition, only 21.4 % and 35.7 % of the institutions had availability of liposomal amphotericin B and voriconazole, respectively.<ce:cross-ref id="crf0052" refid="bib0017">
                        <ce:sup loc="post">17</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para0006" view="all">Antifungal resistance is an increasingly reported problem in Latin America, with descriptions in clinical and environmental samples in Argentina, Brazil, Peru, Colombia,<ce:cross-ref id="crf0053" refid="bib0012">
                        <ce:sup loc="post">12</ce:sup>
                     </ce:cross-ref> and Cuba<ce:cross-ref id="crf0054" refid="bib0018">
                        <ce:sup loc="post">18</ce:sup>
                     </ce:cross-ref>; however, in the work of Falci and Pasqualotto, only 14 % of laboratories had antifungal susceptibility testing for molds.<ce:cross-ref id="crf0055" refid="bib0016">
                        <ce:sup loc="post">16</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para0007" view="all">Therefore, guidelines for diagnosing and treating invasive lung aspergillosis in patients with oncohematological disease, are needed to provide quality health care, improve clinical outcomes, and promote responsible antifungal medications.</ce:para>
                  <ce:section id="sec0002" view="all">
                     <ce:section-title id="cesectitle0004">Scope</ce:section-title>
                     <ce:para id="para0008" view="all">This Evidence-Based Clinical Standard (EBCS) is intended for healthcare personnel caring for adult patients (over 18-years of age) with oncohematologic disease, and for decision-makers or those involved in generating health policies in healthcare institutions in Latin America.</ce:para>
                  </ce:section>
                  <ce:section id="sec0003" view="all">
                     <ce:section-title id="cesectitle0005">Target</ce:section-title>
                     <ce:para id="para0009" view="all">To develop recommendations and algorithms for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease systematically and collaboratively using the best available evidence.</ce:para>
                  </ce:section>
                  <ce:section id="sec0004" view="all">
                     <ce:section-title id="cesectitle0006">Patients considered and clinical aspects addressed</ce:section-title>
                     <ce:para id="para0010" view="all">The clinical practice recommendations and algorithms in this EBCS are for adult patients (18-years old or older) with acute hematologic malignancy or those who have had hematopoietic stem cell transplants, who are asymptomatic or clinically suspected or confirmed diagnosis of invasive lung aspergillosis, and address interventions for prophylaxis, diagnosis, and treatment.</ce:para>
                  </ce:section>
                  <ce:section id="sec0005" view="all">
                     <ce:section-title id="cesectitle0007">Patients not considered and clinical issues not addressed</ce:section-title>
                     <ce:para id="para0011" view="all">This EBCS excludes the following patient groups: children or adolescents (under 18-years-old), pregnant women, adults living with human immunodeficiency virus, patients with a diagnosis or history of solid neoplasm, solid organ transplant recipients, patients with other immunosuppressive conditions or medications, apparently immunocompetent patients, or patients in an intensive care unit with coinfection (e.g., patients with influenza or SARS-CoV-2 infection). The EBCS does not address interventions for prophylaxis, diagnosis, or treatment of aspergillosis in other anatomic locations (e.g., sinuses, central nervous system, bone [i.e., osteomyelitis, septic arthritis]), heart [i.e., endocarditis, myocarditis, pericarditis], skin, etc.).</ce:para>
                  </ce:section>
                  <ce:section id="sec0006" view="all">
                     <ce:section-title id="cesectitle0008">Users to whom the clinical practice guide is directed and healthcare field</ce:section-title>
                     <ce:para id="para0012" view="all">The recommendations and clinical practice algorithms in this EBCS are for health professionals involved in caring for adult patients with acute hematologic neoplasia or those who have had hematopoietic progenitor transplants. This includes specialists in internal medicine, hematology, oncohematology, pulmonology, infectious diseases, critical medicine, and intensive care, as well as nurse practitioners, pharmaceutical chemists, clinical laboratory personnel, and others involved in the care process of this population group.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0007" role="methods" view="all">
                  <ce:section-title id="cesectitle0009">Methods</ce:section-title>
                  <ce:para id="para0013" view="all">The clinical practice recommendations and algorithms were developed through a process led by the National University Hospital of Colombia, in collaboration with the Clinical Research Institute of the National University of Colombia and the National University of Colombia. This process, called Evidence-Based Clinical Standards,<ce:cross-ref id="crf0056" refid="bib0019">
                        <ce:sup loc="post">19</ce:sup>
                     </ce:cross-ref> consists of six phases carried out sequentially: 1) EBCS development group composition; 2) Definition EBCS’ scope and objective; 3) Systematic search for Clinical Practice Guidelines (CPG); 4) Screening, quality evaluation, and selection of CPG; 5) Elaboration of preliminary recommendations and algorithms; 5a) Elaboration a comparative table of evidence; 5b) Review and discussion of recommendations and algorithms by the development group; 6) Final elaboration of recommendations and algorithms; 6a) Review and discussion of recommendations and algorithms in a participatory process with expert consensus.</ce:para>
                  <ce:section id="sec0008" view="all">
                     <ce:section-title id="cesectitle0010">EBCS development group composition</ce:section-title>
                     <ce:para id="para0014" view="all">The EBCS development group consisted of eleven members, including thematic and methodological experts: physicians with training in internal medicine, infectious diseases, pulmonology, oncohematology, and clinical epidemiology, with experience in systematic literature reviews, synthesis and qualification of evidence, and participatory processes (JAC, DAR, MCV, MN, RMR, DC, CAA, FV, LCN, CDB, LE). Prior to the start of activities, each development group member filled out a conflict-of-interest form. If a conflict was declared, it was reviewed to determine how it might affect their participation.</ce:para>
                  </ce:section>
                  <ce:section id="sec0009" view="all">
                     <ce:section-title id="cesectitle0011">Definition of scope and objective</ce:section-title>
                     <ce:para id="para0015" view="all">The scope and objective of the EBCS were defined by answering key questions: Why is it being done? Is there variability in current practice? What is it being done for? Who is it intended for? Who will use it?<ce:cross-ref id="crf0057" refid="bib0020">
                           <ce:sup loc="post">20</ce:sup>
                        </ce:cross-ref> These guided the final formulation of the scope, objective, target patient group, clinical aspects to be addressed, and user population and care setting to which the content of the EBCS is addressed.</ce:para>
                  </ce:section>
                  <ce:section id="sec0010" view="all">
                     <ce:section-title id="cesectitle0012">Systematic search of CPG</ce:section-title>
                     <ce:para id="para0016" view="all">Systematic searches were done to identify CPGs that corresponded to the proposed scope and objective, published between 2014 and 2023, regardless of language.</ce:para>
                     <ce:para id="para0017" view="all">Highly sensitive electronic search strategies were designed. The search was conducted from 6 to July 9, 2023 on the websites of the following CPG compiling and developing bodies: Guidelines International Network (GIN), Agency for Healthcare Research and Quality/National Guidelines Clearinghouse (AHRQ), CMA Infobase: Clinical Practice Guidelines, Catalog of Clinical Practice Guidelines in the National Health System, National Institute for Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), and WHO, and in the Medline and Embase databases using search strategies adapted for each search engine using Boolean, truncation and proximity operators, free text terms, and controlled vocabulary, using key terms such as “Aspergillus”, “Aspergillosis”, “Pulmonary Aspergillosis”, “Hematologic Neoplasms”, “Hematopoietic Stem Cell Transplantation”, and “Bone Marrow Transplantation”. More information on search strategies is presented in the Supplementary Material Table 1.</ce:para>
                  </ce:section>
                  <ce:section id="sec0011" view="all">
                     <ce:section-title id="cesectitle0013">Screening, quality assessment, and selection of CPGs</ce:section-title>
                     <ce:para id="para0018" view="all">Once the search results were obtained, two reviewers (DAR, LCN) independently screened and made the primary selection of references by title and abstract, selecting the references corresponding to CPGs, expert consensus, or generation of recommendations that addressed the aspects defined in the scope and objective of this guideline. Subsequently, two reviewers (DAR, LCN) independently performed the screening and secondary selection of the full text of the selected references, using the criteria from the modified tool 7 of the Methodological Guide for the adoption-adaptation of evidence-based clinical practice guidelines of the Ministry of Health and Social Protection of Colombia<ce:cross-ref id="crf0058" refid="bib0021">
                           <ce:sup loc="post">21</ce:sup>
                        </ce:cross-ref>: CPG with generation of evidence-based recommendations, CPG with a development process and conformation of a developer group, CPG with a reliable evidence search, date of the last update of the search, and use of the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system for the global grading of evidence (<ce:cross-ref id="crf0059" refid="tbl0001">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl0001"/>). References without full text access were discarded. Discrepancies between the two reviewers were resolved through review, discussion, and consensus, or by involving a third reviewer if needed.</ce:para>
                     <ce:para id="para0019" view="all">The CPGs selected after the screening were evaluated for quality by the development group using the AGREE II tool.<ce:cross-ref id="crf0060" refid="bib0022">
                           <ce:sup loc="post">22</ce:sup>
                        </ce:cross-ref> Each guideline was evaluated independently by three reviewers, including a clinical expert and a methodological expert. If any necessary information was identified, additional details were requested from the guideline developers via email. As a result of the quality assessment, CPGs that scored 60 % or higher in methodological rigor and editorial independence domains were identified and selected.</ce:para>
                     <ce:para id="para0020" view="all">Using the methodology described, five references were selected, including the CPG developed by the Infectious Diseases Society of America (IDSA): “Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America”, published in 2018;<ce:cross-ref id="crf0061" refid="bib0023">
                           <ce:sup loc="post">23</ce:sup>
                        </ce:cross-ref> chapters 4 and 7 of the Australian and New Zealand consensus for the treatment of invasive fungal diseases and the use of antifungal agents in the hematology/oncology setting, published in 2021; “Consensus guidelines for antifungal prophylaxis in hematological malignancy and haemopoietic stem cell transplantation, 2021″;<ce:cross-ref id="crf0062" refid="bib0024">
                           <ce:sup loc="post">24</ce:sup>
                        </ce:cross-ref> and “Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021″;<ce:cross-ref id="crf0063" refid="bib0025">
                           <ce:sup loc="post">25</ce:sup>
                        </ce:cross-ref> and the two sections of the Colombian consensus, published in 2022: “Section 1. Colombian consensus on the diagnosis and follow-up of invasive aspergillosis and Aspergillus disease in adult and pediatric patients”<ce:cross-ref id="crf0064" refid="bib0006">
                           <ce:sup loc="post">6</ce:sup>
                        </ce:cross-ref> and “Section 2. Colombian consensus for prophylaxis, treatment and prevention of invasive aspergillosis in adult and pediatric patients”.<ce:cross-ref id="crf0065" refid="bib0026">
                           <ce:sup loc="post">26</ce:sup>
                        </ce:cross-ref> The CPG screening and selection process is summarized in the PRISMA diagram (Supplementary Material Fig. 1).</ce:para>
                  </ce:section>
                  <ce:section id="sec0012" view="all">
                     <ce:section-title id="cesectitle0014">Preparation of proposed recommendations and preliminary algorithm</ce:section-title>
                     <ce:para id="para0021" view="all">A comparative table was prepared based on the reading and extraction of information from the five selected CPGs for the preparation of the proposed recommendations and preliminary algorithm. This table included recommendations for each previously defined clinical aspects to be addressed in the EBCS, along with the evidence certainty and recommendation strength. Informal virtual consensus meetings, lasting approximately 2 h each, were held with all development group members. They presented and reviewed the information from the comparative table and discussed and constructed the proposed recommendations and preliminary algorithm of the EBCS.</ce:para>
                  </ce:section>
                  <ce:section id="sec0013" view="all">
                     <ce:section-title id="cesectitle0015">Expert consensus</ce:section-title>
                     <ce:para id="para0022" view="all">Finally, the proposed recommendations and preliminary algorithm were reviewed in an expert consensus by professionals from Argentina (FR), Brazil (MN, DC), Chile (RMR, LT, MS), Colombia (JAC, DAR, DAR, CAA, FV, LCN, CDB, LE, SIC, EPV, BLG, AMCR, DLO), Mexico (DEC, PC, JLS), Peru (LEC), and Dominican Republic (RAR). These professionals, trained in infectious diseases (JAC, RMR, CAA, LCN, SIC, LT, DEC, LEC, EPV, FR, PC, RAR, MN), microbiology (BLG, AMCR), diagnostic imaging (DLO), pulmonology (DC, FV, JLS), oncohematology (LE, MS), and internal medicine (CDB, DAR), provided input from various specialties involved in diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease in Latin America. Each consensus participant completed a conflict-of-interest form. Any declared conflicts were analyzed to determine their impact on participation.</ce:para>
                     <ce:para id="para0023" view="all">Two virtual consensus meetings, each lasting approximately 4 h, were held. During the meetings, the proposed recommendations and preliminary algorithm were presented and reviewed, and using a real-time Delphi methodology, the formulation and construction of the recommendations and final algorithm were carried out. Voting was carried out anonymously and electronically, to evaluate the degree of agreement with each recommendation and section of the algorithm. A Likert scale from 1 to 9 was used, where 1 corresponded to strongly disagree, 5 to neither agree nor disagree, and 9 to completely agree.<ce:cross-ref id="crf0066" refid="bib0029">
                           <ce:sup loc="post">29</ce:sup>
                        </ce:cross-ref> Agreement was defined as agreement when ≥ 60 % of the votes were in the 4–9 range and &lt; 20 % of the votes were in the 4–6 range of the scale. No agreement (i.e., no consensus) was considered when ≥ 40 % of the votes were in the range of 1–3. If no consensus was considered in the first round, a discussion and a new round of voting were held, with a maximum of three rounds allowed for each question.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0014" role="results" view="all">
                  <ce:section-title id="cesectitle0016">Results</ce:section-title>
                  <ce:section id="sec0015" view="all">
                     <ce:section-title id="cesectitle0017">Flowchart</ce:section-title>
                     <ce:para id="para0024" view="all">
                        <ce:cross-ref id="crf0067" refid="fig0001">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig0001"/> shows the flowchart for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease.</ce:para>
                     <ce:para id="para0025" view="all">
                        <ce:cross-ref id="crf0068" refid="fig0002">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig0002"/> shows Section 1 of the flowchart (primary antifungal prophylaxis of the patient with oncohematologic disease at high-risk of invasive lung aspergillosis).</ce:para>
                     <ce:para id="para0026" view="all">
                        <ce:bold>
                           <ce:italic>Recommendations flowchart Section 1:</ce:italic>
                        </ce:bold> Primary antifungal prophylaxis of the patient with oncohematologic disease at high-risk of invasive lung aspergillosis.<ce:list id="celist0001">
                           <ce:list-item id="celistitem0001">
                              <ce:para id="para0027" view="all">1) Primary antifungal prophylaxis is recommended for patients with the following conditions (Strong recommendation, high-quality evidence, GRADE)<ce:cross-ref id="crf0069" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref>:<ce:list id="celist0002">
                                    <ce:list-item id="celistitem0002">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0028" view="all">Severe graft-versus-host disease.</ce:para>
                                    </ce:list-item>
                                    <ce:list-item id="celistitem0003">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0029" view="all">Acute myeloid leukemia or myelodysplastic syndromes in induction with intensive chemotherapy.</ce:para>
                                    </ce:list-item>
                                 </ce:list>
                              </ce:para>
                              <ce:para id="para1027" view="all">It is recommended to individualize the decision to initiate primary antifungal prophylaxis in patients with the following conditions (expert recommendation):<ce:cross-refs id="opt2dpYbKIxvK" refid="bib0024 bib0026">
                                    <ce:sup loc="post">24,26</ce:sup>
                                 </ce:cross-refs>
                                 <ce:list id="celist0003">
                                    <ce:list-item id="celistitem0004">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0031" view="all">Administration of corticosteroid doses equivalent to &gt;1 mg/kg of prednisolone and neutrophils less than 1 × 10<ce:sup loc="post">9</ce:sup>/L for &gt;1-week.</ce:para>
                                    </ce:list-item>
                                    <ce:list-item id="celistitem0005">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0032" view="all">Administration of corticosteroid doses equivalent to &gt;2 mg/kg of prednisolone for &gt;2-weeks.</ce:para>
                                    </ce:list-item>
                                    <ce:list-item id="celistitem0006">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0033" view="all">Neutrophils &lt;0.1 × 10<ce:sup loc="post">9</ce:sup>/L for &gt;3-weeks, or &lt;0.5 × 10<ce:sup loc="post">9</ce:sup>/L for &gt;5-weeks.</ce:para>
                                    </ce:list-item>
                                    <ce:list-item id="celistitem0007">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0034" view="all">Allogeneic transplantation of unrelated, mismatched hematopoietic stem cells or cord blood.</ce:para>
                                    </ce:list-item>
                                    <ce:list-item id="celistitem1007">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para1034" view="all">Acute lymphoblastic leukemia in induction/reinduction.</ce:para>
                                    </ce:list-item>
                                 </ce:list>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0008">
                              <ce:para id="para0036" view="all">2) Due to the absence of high-level evidence, the routine use of primary antifungal prophylaxis is not recommended for most patients with oncohematologic disease on therapy undergoing new hematologic therapies. The decision to initiate primary antifungal prophylaxis should be individualized for each patient (expert recommendation).<ce:cross-ref id="crf0070" refid="bib0024">
                                    <ce:sup loc="post">24</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0009">
                              <ce:para id="para0037" view="all">3) Posaconazole is recommended as primary antifungal prophylaxis for patients at high-risk of invasive lung aspergillosis (strong recommendation, high-quality evidence, GRADE)<ce:cross-ref id="crf0071" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0072" refid="bib0024">
                                    <ce:sup loc="post">24</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0073" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0074" refid="tbl0002">Table 2</ce:cross-ref>
                                 <ce:float-anchor refid="tbl0002"/>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0010">
                              <ce:para id="para0038" view="all">4) Voriconazole is recommended as an alternative for primary antifungal prophylaxis if posaconazole is contraindicated and/or not possible (Strong recommendation, moderate-quality evidence, GRADE)<ce:cross-ref id="crf0075" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0076" refid="bib0024">
                                    <ce:sup loc="post">24</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0077" refid="tbl0002">Table 2</ce:cross-ref>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0011">
                              <ce:para id="para0039" view="all">5) The expert panel considers that there is insufficient evidence to recommend itraconazole-SUBA (SUper BioAvailability) as primary antifungal prophylaxis for patients at high-risk of invasive lung aspergillosis.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0012">
                              <ce:para id="para0040" view="all">6) The expert panel considers that there is insufficient evidence to recommend isavuconazole as primary antifungal prophylaxis for patients at high-risk for invasive lung aspergillosis.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0013">
                              <ce:para id="para0041" view="all">7) An echinocandin, preferably caspofungin, is recommended as an alternative for primary antifungal prophylaxis if azoles are contraindicated and/or not possible. The use of micafungin could be considered (strong recommendation, high-quality evidence, GRADE)<ce:cross-ref id="crf0078" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0079" refid="tbl0002">Table 2</ce:cross-ref>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0014">
                              <ce:para id="para0042" view="all">8) Liposomal amphotericin B is recommended as an alternative for primary antifungal prophylaxis if echinocandins are contraindicated and/or not possible (conditional recommendation, moderate-quality evidence, GRADE)<ce:cross-ref id="crf0080" refid="bib0024">
                                    <ce:sup loc="post">24</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0081" refid="tbl0002">Table 2</ce:cross-ref>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0015">
                              <ce:para id="para0043" view="all">9) The expert panel considers that there is insufficient evidence to recommend nebulized amphotericin B as primary antifungal prophylaxis for patients at high-risk for invasive lung aspergillosis.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0016">
                              <ce:para id="para0044" view="all">10) Good practice point: If no other primary antifungal prophylaxis options are available for filamentous fungi, consider using fluconazole (400 mg/day orally) as prophylaxis for invasive candidiasis, associated with an appropriate screening strategy for filamentous fungi, and refer the patient to a center where antifungal prophylaxis against filamentous fungi options are available.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0017">
                              <ce:para id="para0045" view="all">11) In cases of suspected gap infection, verify adherence to antifungal prophylaxis, check for possible drug interactions, and other relevant factors (strong recommendation, high-quality evidence, GRADE),<ce:cross-ref id="crf0082" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref> and the diagnostic procedure for gap infection should be initiated.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0018">
                              <ce:para id="para0046" view="all">12) It is recommended to maintain primary antifungal prophylaxis for the duration of intense immunosuppression (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0083" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0084" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref> The decision to discontinue antifungal prophylaxis should be individualized, taking into account neutrophil recovery (&gt; 0.5 × 10<ce:sup loc="post">9</ce:sup>/L) and tapering of the dose of immunosuppressive drugs used in graft-versus-host disease.<ce:cross-ref id="crf0085" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0086" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                        </ce:list>Good practice point: If primary antifungal prophylaxis was started with an antifungal other than an azole, consider switching to an extended-spectrum azole for continued prophylaxis.</ce:para>
                     <ce:para id="para0048" view="all">In <ce:cross-ref id="crf0087" refid="fig0003">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig0003"/>, section 2 of the flowchart (diagnostic approach to the patient with oncohematologic disease with cynical suspicion of invasive lung aspergillosis) is presented.</ce:para>
                     <ce:para id="para0049" view="all">
                        <ce:italic>
                           <ce:bold>Recommendations flowchart Section 2:</ce:bold>
                        </ce:italic> Diagnosis of the patient with oncohematologic disease with cynical suspicion of invasive lung aspergillosis.<ce:list id="celist0005">
                           <ce:list-item id="celistitem0019">
                              <ce:para id="para0050" view="all">13) For patients at high-risk for invasive lung aspergillosis who do not receive primary antifungal prophylaxis against filamentous fungi, serum-based galactomannan antigen testing, within a serial measurement protocol (two or three times per week), is recommended for early detection and/or diagnosis of invasive lung aspergillosis (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0088" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                              <ce:para id="para1050" view="all">For patients at high-risk for invasive lung aspergillosis on primary antifungal prophylaxis against filamentous fungi who show signs suggestive of invasive lung aspergillosis, galactomannan antigen testing from serum is recommended, within a protocol of measurements per clinical indication (2 or 3 consecutive days), for early detection and/or diagnosis of invasive lung aspergillosis (expert recommendation).<ce:cross-refs id="crf0089" refid="bib0031 bib0032 bib0033 bib0034">
                                    <ce:sup loc="post">31–34</ce:sup>
                                 </ce:cross-refs>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0020">
                              <ce:para id="para0052" view="all">14) For patients at high-risk for invasive lung aspergillosis, serum galactomannan antigen testing is recommended for diagnosing invasive lung aspergillosis (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0091" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0021">
                              <ce:para id="para0053" view="all">15) The expert panel considers that there is insufficient evidence to recommend using 1,3-β-d-glucan, as it has a limited role in ruling out or making the exclusive diagnosis of invasive aspergillosis.<ce:cross-ref id="crf0092" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0022">
                              <ce:para id="para0054" view="all">16) For patients at high-risk for invasive lung aspergillosis, tests that detect specific antibodies and/or <ce:italic>Aspergillus</ce:italic> spp. precipitation are not recommended for diagnosing invasive lung aspergillosis (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0093" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0023">
                              <ce:para id="para0055" view="all">17) High-resolution/thin-slice Computed Tomography (CT) of the chest is recommended whenever there is clinical suspicion of invasive lung aspergillosis, regardless of the results of chest radiography (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0094" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0095" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0024">
                              <ce:para id="para0056" view="all">18) Routine use of contrast-enhanced chest CT is not recommended for suspected invasive lung aspergillosis (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0096" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0097" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0025">
                              <ce:para id="para0057" view="all">19) Good practice point: CT pulmonary angiography can improve diagnosis of invasive lung aspergillosis in patients with oncohematologic disease by demonstrating the “vascular occlusion sign”, which is more sensitive than other common CT findings. The search for this sign can be performed in patients with nodular lesions (central &gt; 10 mm or peripheral &gt; 12 mm) or suspected pulmonary infarction, considering the patient's renal function.<ce:cross-refs id="crf0098" refid="bib0035 bib0036 bib0037">
                                    <ce:sup loc="post">35–37</ce:sup>
                                 </ce:cross-refs>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0026">
                              <ce:para id="para0058" view="all">20) For patients at high-risk for invasive lung aspergillosis with clinical findings of hemoptysis, it is recommended to perform arterial phase CT angiography to identify the possible site of vessel erosion (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0100" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0027">
                              <ce:para id="para0059" view="all">21. Good practice point: If the galactomannan antigen test is positive and high-resolution thin-slice/thin-slice CT scan of the chest is normal, consider looking for invasive aspergillosis at other anatomic sites or invasive infection by another filamentous fungus.<ce:cross-ref id="crf0101" refid="bib0038">
                                    <ce:sup loc="post">38</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0102" refid="bib0039">
                                    <ce:sup loc="post">39</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0028">
                              <ce:para id="para0060" view="all">22. For suspected invasive lung aspergillosis, bronchoscopy with bronchoalveolar lavage* is recommended (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0103" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0104" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0029">
                              <ce:para id="para0061" view="all">* Refractory thrombocytopenia is an absolute contraindication for bronchoalveolar lavage.<ce:cross-ref id="crf0105" refid="bib0040">
                                    <ce:sup loc="post">40</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0106" refid="bib0041">
                                    <ce:sup loc="post">41</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0030">
                              <ce:para id="para0062" view="all">23. Good practice point: If there is no response to treatment, atypical findings on chest CT scan, or suspicion of coinfection, consider performing lung biopsy*.<ce:cross-ref id="crf0107" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0108" refid="bib0042">
                                    <ce:sup loc="post">42</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0031">
                              <ce:para id="para0063" view="all">* Severe hypoxemia or severe alterations of hemostasis such as thrombocytopenia refractory to platelet transfusion and thrombocytopenia &lt;50,000 µL are absolute contraindications for lung biopsy.<ce:cross-ref id="crf0109" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0032">
                              <ce:para id="para0064" view="all">24. If peripheral nodular lesions are present and if Endobronchial Endoscopic Ultrasound (EBUS) is available, consider using it in lung biopsy (expert recommendation).<ce:cross-ref id="crf0110" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0033">
                              <ce:para id="para0065" view="all">25. For patients at high-risk for invasive lung aspergillosis, it is recommended to routinely perform direct microscopic examination and mycological culture of respiratory tract samples (like induced sputum, tracheal aspirates, bronchoalveolar lavage) to recover the possible etiological agent involved in the infectious process (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0111" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0112" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0034">
                              <ce:para id="para0066" view="all">26. For patients at high-risk for invasive lung aspergillosis, using optical targets (Calcofluor white™, Uvitex 2B, Blancophor™), or Grocott's Methenamine Silver (GMS) or Periodic Acid-Schiff (PAS) staining during direct microscopic examination of respiratory tract and/or tissue samples from the affected site according to institutional protocols is recommended (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0113" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0035">
                              <ce:para id="para0067" view="all">27. It is recommended to submit fluid and tissue specimens in adequate quantities for simultaneous histopathological/cytological and microbiological examination (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0114" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0036">
                              <ce:para id="para0068" view="all">28. For patients at high-risk for invasive lung aspergillosis, consider using lateral flow assay to test for galactomannan antigen in bronchoalveolar lavage as a quick and easy diagnostic tool (conditional recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0115" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref> The expert panel considers that there is not enough high-quality evidence to favor this method over other techniques for measuring this biomarker.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0037">
                              <ce:para id="para0069" view="all">29. For patients at high-risk for invasive lung aspergillosis, it is recommended to detect <ce:italic>Aspergillus</ce:italic> spp. DNA using PCR from respiratory tract specimens (bronchoalveolar lavage and/or biopsy) and/or whole blood (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0116" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0038">
                              <ce:para id="para0070" view="all">30. Good practice point: In scenarios of isolates with atypical growth or suspected resistance, species identification by molecular methods should be used.<ce:cross-ref id="crf0117" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0039">
                              <ce:para id="para0071" view="all">31. Good practice point: For molecular studies, previously validated and implemented laboratory tests should be used.<ce:cross-refs id="crf0118" refid="bib0043 bib0044 bib0045">
                                    <ce:sup loc="post">43–45</ce:sup>
                                 </ce:cross-refs>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0040">
                              <ce:para id="para0072" view="all">32. Good practice point: The results of diagnostic tests must be interpreted within the context of specimen type and the history of antifungal drug use.<ce:cross-ref id="crf0120" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0041">
                              <ce:para id="para0073" view="all">33. A joint interpretation of clinical, imaging, microbiology, and pathology criteria is recommended for diagnosing invasive lung aspergillosis (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0121" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0042">
                              <ce:para id="para0074" view="all">34. It is recommended that invasive lung aspergillosis be considered in patients with the “halo sign” in the high-resolution CT scan of the chest (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0122" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0043">
                              <ce:para id="para0075" view="all">35. In patients at high-risk for invasive lung aspergillosis, isolation of an <ce:italic>Aspergillus</ce:italic> species from respiratory tract specimens (induced sputum, tracheal aspirates, bronchoalveolar lavage) and/or biopsy of the involved site is highly suggestive of invasive lung aspergillosis (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0123" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0044">
                              <ce:para id="para0076" view="all">36. For patients at high-risk for invasive lung aspergillosis, it is recommended that <ce:italic>Aspergillus</ce:italic> species recovered from respiratory tract specimens (induced sputum, tracheal aspirates, bronchoalveolar lavage) and/or biopsy of the affected site be identified to complex level. All isolates from the <ce:italic>A. fumigati</ce:italic> section/complex should be identified to species level (strong recommendation, high-quality evidence, GRADE).<ce:cross-ref id="crf0124" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0045">
                              <ce:para id="para0077" view="all">37. It is recommended to identify <ce:italic>Aspergillus</ce:italic> species involved in invasive aspergillosis by macroscopic and microscopic examination of primary cultures. The use of special identification media (2 % malt extract agar and/or Czapek-Dox agar), incubated at 25 °C–30 °C, 37 °C, and 50 °C (Strong recommendation, moderate-quality evidence, GRADE) is recommended.<ce:cross-ref id="crf0125" refid="bib0006">
                                    <ce:sup loc="post">6</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0126" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0046">
                              <ce:para id="para0078" view="all">38. Consider using proteomic techniques (MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry), if available, for identifying <ce:italic>Aspergillus</ce:italic> species (conditional recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0127" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0047">
                              <ce:para id="para0079" view="all">39. Antifungal susceptibility testing of Aspergillus isolates during initial infection is not routinely recommended. Performing antifungal susceptibility testing, using a reference method, is reserved for the setting of suspected failure and/or refractoriness to antifungal therapy, or for epidemiological purposes (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0128" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                        </ce:list>
                     </ce:para>
                     <ce:para id="para0080" view="all">
                        <ce:cross-ref id="crf0129" refid="fig0004">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig0004"/> shows Section 3 of the flowchart (patient management of the patient with oncohematologic disease diagnosed with invasive lung aspergillosis).</ce:para>
                     <ce:para id="para0081" view="all">
                        <ce:bold>
                           <ce:italic>Recommendations Section 3 of the flowchart:</ce:italic>
                        </ce:bold> Treatment of the patient with oncohematologic disease diagnosed with invasive lung aspergillosis<ce:list id="celist0007">
                           <ce:list-item id="celistitem0048">
                              <ce:para id="para0082" view="all">40. Start empirical antifungal treatment against filamentous fungi for patients with prolonged neutropenia (&gt; 10-days), no prior antifungal prophylaxis against filamentous fungi, with clinical signs/symptoms of invasive lung aspergillosis, and suggestive findings of invasive aspergillosis on chest CT scan, and without availability and/or timely access to clinical laboratory diagnostic tools (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0130" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0049">
                              <ce:para id="para0083" view="all">41. In patients with previous antifungal prophylaxis against filamentous fungi, the choice of antifungal treatment against filamentous fungi is recommended based on the type of prophylaxis administered (strong recommendation, high-quality evidence, GRADE)<ce:cross-ref id="crf0131" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0132" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref>:<ce:list id="celist0008">
                                    <ce:list-item id="celistitem0050">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0084" view="all">If the patient has received prophylaxis with an extended-spectrum azole, liposomal amphotericin B is recommended for antifungal treatment (<ce:cross-ref id="crf0133" refid="tbl0003">Table 3</ce:cross-ref>
                                          <ce:float-anchor refid="tbl0003"/>).</ce:para>
                                    </ce:list-item>
                                    <ce:list-item id="celistitem0051">
                                       <ce:label>•</ce:label>
                                       <ce:para id="para0085" view="all">If the patient has received prophylaxis with echinocandin, the use of an extended-spectrum azole as an antifungal treatment is recommended. Consider the use of liposomal amphotericin B as an alternative (<ce:cross-ref id="crf0134" refid="tbl0003">Table 3</ce:cross-ref>).</ce:para>
                                    </ce:list-item>
                                 </ce:list>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0052">
                              <ce:para id="para0086" view="all">42. In patients without previous antifungal prophylaxis against filamentous fungi, the use of an extended-spectrum azole (voriconazole, isavuconazole, or posaconazole) is recommended as an antifungal treatment (strong recommendation, high-quality evidence, GRADE)<ce:cross-ref id="crf0135" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0136" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0137" refid="tbl0003">Table 3</ce:cross-ref>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0053">
                              <ce:para id="para0087" view="all">43. Good practice point: When using extended-spectrum azoles as an antifungal treatment for invasive lung aspergillosis, potential drug–drug interactions should be carefully reviewed<ce:cross-ref id="crf0138" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0139" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0140" refid="bib0046">
                                    <ce:sup loc="post">46</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0141" refid="tbl0004">Table 4</ce:cross-ref>
                                 <ce:float-anchor refid="tbl0004"/>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0054">
                              <ce:para id="para0088" view="all">44. Good practice point: If drug–drug interaction, therapeutic failure, and/or toxicity is suspected, use serum concentration measurements of voriconazole and/or posaconazole, if available, to guide antifungal treatment<ce:cross-ref id="crf0142" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0143" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0144" refid="bib0046">
                                    <ce:sup loc="post">46</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0145" refid="tbl0005">Table 5</ce:cross-ref>
                                 <ce:float-anchor refid="tbl0005"/>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0055">
                              <ce:para id="para0089" view="all">45. Good practice point: The use of itraconazole, or itraconazole-SUBA as an antifungal treatment for invasive lung aspergillosis is discouraged.<ce:cross-ref id="crf0146" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0056">
                              <ce:para id="para0090" view="all">46. Consider using liposomal amphotericin B as an alternative for antifungal treatment, when the use of azoles is contraindicated and/or not possible (strong recommendation, moderate-quality evidence, GRADE)<ce:cross-ref id="crf0147" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0148" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0149" refid="tbl0003">Table 3</ce:cross-ref>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0057">
                              <ce:para id="para0091" view="all">47. Good practice point: For patients with renal failure who cannot receive extended-spectrum azole, liposomal amphotericin B can be used as an antifungal treatment, and renal replacement therapy can be initiated.<ce:cross-refs id="crf0150" refid="bib0047 bib0048 bib0049">
                                    <ce:sup loc="post">47–49</ce:sup>
                                 </ce:cross-refs>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0058">
                              <ce:para id="para0092" view="all">48. Use lipid complex amphotericin B as an antifungal treatment if liposomal amphotericin B is contraindicated and/or not possible (Expert recommendation)<ce:cross-ref id="crf0152" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref> (<ce:cross-ref id="crf0153" refid="tbl0003">Table 3</ce:cross-ref>).</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0059">
                              <ce:para id="para0093" view="all">49. The use of amphotericin B deoxycholate as an antifungal treatment is not recommended (expert recommendation).<ce:cross-ref id="crf0154" refid="bib0026">
                                    <ce:sup loc="post">26</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0060">
                              <ce:para id="para0094" view="all">50. Good practice point: Avoid using echinocandins (caspofungin, anidulafungin or micafungin) in monotherapy as an antifungal treatment if azoles and polyenes are contraindicated and/or not possible.<ce:cross-ref id="crf0155" refid="bib0050">
                                    <ce:sup loc="post">50</ce:sup>
                                 </ce:cross-ref>
                                 <ce:sup loc="post">,</ce:sup>
                                 <ce:cross-ref id="crf0156" refid="bib0051">
                                    <ce:sup loc="post">51</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0061">
                              <ce:para id="para0095" view="all">51. It is recommended that treatment of invasive lung aspergillosis continue for 6–12 weeks, depending largely on the degree and duration of immunosuppression and evidence of disease improvement (strong recommendation, low-quality evidence, GRADE).<ce:cross-ref id="crf0157" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0062">
                              <ce:para id="para0096" view="all">52. Consider changing the route of administration of antifungal treatment from intravenous to oral route in clinically stable patients with reliable enteric absorption (expert recommendation).<ce:cross-ref id="crf0158" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0063">
                              <ce:para id="para0097" view="all">53. Good practice point: In scenarios of therapeutic failure, consider switching to another class of drug, always individualizing the scenario for each patient.<ce:cross-ref id="crf0159" refid="bib0025">
                                    <ce:sup loc="post">25</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0064">
                              <ce:para id="para0098" view="all">54. The expert panel considers that there is insufficient high-quality evidence to recommend for or against the use of combination antifungal therapy for treating invasive lung aspergillosis.</ce:para>
                           </ce:list-item>
                           <ce:list-item id="celistitem0065">
                              <ce:para id="para0099" view="all">55. For patients who have successfully treated invasive lung aspergillosis and will undergo a new period of immunosuppression, it is recommended to initiate secondary antifungal prophylaxis to prevent recurrence (strong recommendation, moderate-quality evidence, GRADE).<ce:cross-ref id="crf0160" refid="bib0023">
                                    <ce:sup loc="post">23</ce:sup>
                                 </ce:cross-ref>
                              </ce:para>
                           </ce:list-item>
                        </ce:list>
                     </ce:para>
                  </ce:section>
                  <ce:section id="sec0016" view="all">
                     <ce:section-title id="cesectitle0018">Implementation of EBCS</ce:section-title>
                     <ce:para id="para0100" view="all">To ensure safe and quality care for adult patients with oncohematological disease in Latin America, the implementation of this EBCS for the diagnosis and treatment of invasive lung aspergillosis in this population is proposed within the framework of the activities that are part of the optimization programs in using antifungals, considering for its adequate management the measurement of the indicators presented in <ce:cross-ref id="crf0161" refid="tbl0006">Table 6</ce:cross-ref>
                        <ce:float-anchor refid="tbl0006"/>, proposed as control points, for their measurement and obligatory reporting with the frequency that each institution considers pertinent according to its daily clinical practice.</ce:para>
                     <ce:para id="para0101" view="all">To implement this guide, the following dissemination tools will be used to facilitate its access to health professionals: the publication of the EBCS in The Brazilian Journal of Infectious Diseases, and the inclusion of the algorithms and recommendations in online courses and mobile applications.</ce:para>
                  </ce:section>
                  <ce:section id="sec0017" view="all">
                     <ce:section-title id="cesectitle0019">EBCS update</ce:section-title>
                     <ce:para id="para0102" view="all">This EBCS should be updated within a maximum of five years, following the methodology and standards that have been established for developing evidence-based recommendations. The topics may be reconsidered according to the need for publication of new evidence.</ce:para>
                  </ce:section>
                  <ce:section id="sec0018" view="all">
                     <ce:section-title id="cesectitle0020">Ethical considerations</ce:section-title>
                     <ce:para id="para0103" view="all">The regulations outlined in national and international legislation have guided the development of this work, adhering to the ethical and bioethical standards for scientific research.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0019" role="funding" view="all">
                  <ce:section-title id="cesectitle0021">Funding source</ce:section-title>
                  <ce:para id="para0104" view="all">This document has been developed as part of the “Antifungal administration programs in a Latin American country” project of the Universidad Nacional de Colombia, financed by a grant from Pfizer Inc. The project's objectives included developing recommendations for diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease in Latin America. In addition, the publication was supported by the School of Medicine of the Universidad Nacional de Colombia, through funding for the edition of the manuscript in English.</ce:para>
               </ce:section>
               <ce:section id="sec0020" view="all">
                  <ce:section-title id="cesectitle0022">Editorial independence</ce:section-title>
                  <ce:para id="para0105" view="all">The content of this document was developed entirely independently, free from the influence of the funding entity, Pfizer Inc., which did not participate or have any role in the different phases of the development of the EBCS, including among others: the formation of the development group; the systematic search, screening, and selection of CPG; the analysis and interpretation of the evidence; the formation of the expert consensus; the generation of recommendations and preparation of the algorithms; the drafting of the manuscript; and the decision to publish. None of the professionals who were part of the development group, or the expert consensus, received any type of payment or incentive for their participation in or contributions to the development of this document.</ce:para>
               </ce:section>
               <ce:section id="sec0021" view="all">
                  <ce:section-title id="cesectitle0023">Authors’ contribution</ce:section-title>
                  <ce:para id="para0106" view="all">JAC conceptualized and led the EBCS. MCV performed the methodological coordination, systematic search of CPGs, and preparation of the comparative evidence table. JAC, MCV, DAR, LCN, and CDB contributed to the screening, quality assessment, selection of CPG, and wrote the first draft of the manuscript and the final version. JAC, MCV, DAR, LCN, CDB, MN, RMR, DC, CAA, FV, and LE participated as members of the development group in defining the scope and objective of the EBCS, and in the process of reviewing, discussing, and drafting the proposed recommendations and preliminary algorithm. SIC, LT, DEC, LEC, EPV, FR, PC, RAR, BLG, AMCR, DLO, JLS, and MS participated as members of the expert consensus in the review, discussion, and final elaboration of recommendations and algorithms. The initial iteration of the manuscript was reviewed by all authors, and the final version was read and approved by all authors.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0001" view="all">
               <ce:section-title id="cesectitle0024">Conflicts of interest</ce:section-title>
               <ce:para id="para0108" view="all">The following authors declared no conflict of interest: DAR, DC, DCN, LCN, CD, SIC, LEC, BLG, AMCR, DLO. The following authors declared conflict of interest: JAC (Pfizer), MCV (Pfizer), RMR (Gilead Sciences, Gador, Pfizer), CAA (Moderna, Merck Sharp &amp; Dohme, GlaxoSmithKline, Becton Dickinson, Pfizer), MN (Pfizer, Merck Sharp &amp; Dohme, Knight Therapeutics), LT (Gador, Gilead Sciences, Knight Therapeutics), DEC (IMMY), EPV (Pfizer), FR (Gador, Gilead Sciences, Knight Therapeutics), PC (Pfizer, Merck Sharp &amp; Dohme), RAR (Pfizer, SteinCares, Merck Sharp &amp; Dohme). With no stated interests identified that could be considered potentially conflicting with the primary interest of this EBCS.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0001" view="all">
               <ce:section-title id="cesectitle0025">Acknowledgements</ce:section-title>
               <ce:para id="para0109" view="all">We would like to thank Professor Flavio Queiroz-Telles, Department of Public Health, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil, as external expert peer reviewer for his critical review of the draft manuscript, his feedback and comments.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="sec0022" view="compact-standard">
                  <ce:section-title id="cesectitle9001">Supplementary materials</ce:section-title>
                  <ce:para id="para0001a" view="all">Supplementary material associated with this article can be found, in the online version, at <ce:inter-ref id="interref0001" xlink:href="https://doi.org/10.1016/j.bjid.2025.104517" xlink:type="simple">doi:10.1016/j.bjid.2025.104517</ce:inter-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0023" view="extended">
                  <ce:label>Appendix</ce:label>
                  <ce:section-title id="cesectitle9002">Supplementary materials</ce:section-title>
                  <ce:para id="para0107a" view="all">
                     <ce:display>
                        <ce:e-component id="ecom0001">
                           <ce:alt-text id="alt0011" role="short">Image, application 1</ce:alt-text>
                           <ce:link id="celink0005" locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S1413867025000200/mmc1"/>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebibl1" view="all">
               <ce:section-title id="cesectitle0026">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec1" view="all">
                  <ce:bib-reference id="bib0001">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0001">
                        <sb:comment>3rd</sb:comment>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cadena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.F.</ce:given-name>
                                 <ce:surname>Patterson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Invasive aspergillosis: current strategies for diagnosis and management</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Infect Dis Clin North Am</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>125</sb:first-page>
                              <sb:last-page>142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0001">Cadena J., Thompson G.R., 3rd, Patterson T.F. Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin North Am. 2016;30:125–42.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0002">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0002">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pagano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Akova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dimopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Herbrecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Drgona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Blijlevens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Antimicrob Chemother</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 1</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>i5</sb:first-page>
                              <sb:last-page>14</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0002">Pagano L., Akova M., Dimopoulos G., Herbrecht R., Drgona L., Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:i5–14.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0003">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0003">
                        <sb:comment>3rd</sb:comment>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aspergillus infections</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N Engl J Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>385</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1496</sb:first-page>
                              <sb:last-page>1509</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0003">Thompson G.R., 3rd, Young J.H. Aspergillus infections. N Engl J Med. 2021;385:1496–509.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0004">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0004">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Ullmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Lipton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Vesole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chandrasekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Langston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Tarantolo</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N Engl J Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>356</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>335</sb:first-page>
                              <sb:last-page>347</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0004">Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0005">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Cornely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Maertens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Winston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Perfect</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Ullmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Walsh</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N Engl J Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>356</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>348</sb:first-page>
                              <sb:last-page>359</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0005">Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0006">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0006">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rivas-Pinedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Oñate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Berrio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Celis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fernández-Suarez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Castañeda- Luquerna</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Section 1. Colombian consensus on the diagnosis and follow-up of invasive aspergillosis and Aspergillus disease in adult and pediatric patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Infectio</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2022</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>262</sb:first-page>
                              <sb:last-page>296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0006">Rivas-Pinedo P., Oñate J.M., Berrio I., Celis A.M., Fernández-Suarez H., Castañeda- Luquerna X., et al. Section 1. Colombian consensus on the diagnosis and follow-up of invasive aspergillosis and Aspergillus disease in adult and pediatric patients. Infectio. 2022;26:262–96.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0007">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0007">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Rabagliati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.G.</ce:given-name>
                                 <ce:surname>Fuentes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.M.</ce:given-name>
                                 <ce:surname>Guzmán</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.E.</ce:given-name>
                                 <ce:surname>Orellana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Oporto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.I.</ce:given-name>
                                 <ce:surname>Aedo</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enfermedad fúngica invasora en pacientes hemato-oncológicos y receptores de trasplante de precursores hematopoyéticos bajo la perspectiva de los criterios diagnósticos EORTC/MSG</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Revista Chilena Infectología</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>212</sb:first-page>
                              <sb:last-page>219</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0007">Rabagliati B.R., Fuentes L.G., Guzmán D.A.M., Orellana U.E., Oporto C.J., Aedo C.I., et al. Enfermedad fúngica invasora en pacientes hemato-oncológicos y receptores de trasplante de precursores hematopoyéticos bajo la perspectiva de los criterios diagnósticos EORTC/MSG. Revista Chilena Infectología. 2009;26:212–9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0008">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0008">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.R.</ce:given-name>
                                 <ce:surname>Aquino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.B.</ce:given-name>
                                 <ce:surname>Verçosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Falhauber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.W.</ce:given-name>
                                 <ce:surname>Lunardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Silla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Pasqualotto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Distribution of filamentous fungi causing invasive fungal disease at the Haematological Unit, Hospital de Clínicas de Porto Alegre, Brazil</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Braz J Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>277</sb:first-page>
                              <sb:last-page>280</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0008">Aquino V.R., Verçosa E.B., Falhauber G., Lunardi L.W., Silla L., Pasqualotto A.C. Distribution of filamentous fungi causing invasive fungal disease at the Haematological Unit, Hospital de Clínicas de Porto Alegre, Brazil. Braz J Infect Dis. 2010;14:277–80.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0009">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0009">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sifuentes-Osornio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Corzo-Leon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Ponce-de-Leon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epidemiology of invasive fungal infections in Latin America</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr Fung Infect Rep</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23</sb:first-page>
                              <sb:last-page>34</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0009">Sifuentes-Osornio J., Corzo-Leon D.E., Ponce-de-Leon L.A. Epidemiology of invasive fungal infections in Latin America. Curr Fung Infect Rep. 2012;6:23–34.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goyeneche-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rodriguez-Oyuela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sanchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Firacative</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical and epidemiological profile of patients with invasive aspergillosis from a Fourth Level hospital in Bogota, Colombia: a retrospective study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Fungi (Basel)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1092</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0010">Goyeneche-Garcia A., Rodriguez-Oyuela J., Sanchez G., Firacative C. Clinical and epidemiological profile of patients with invasive aspergillosis from a Fourth Level hospital in Bogota, Colombia: a retrospective study. J Fungi (Basel). 2021;7:1092.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0011">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0011">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Denning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antifungal drug resistance: an update</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur J Hosp Pharm</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2022</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>109</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0011">Denning D.W. Antifungal drug resistance: an update. Eur J Hosp Pharm. 2022;29:109–12.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0012">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0012">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Macedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Leonardelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gamarra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Garcia-Effron</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Emergence of triazole resistance in Aspergillus spp</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:book-series>
                                 <sb:series>
                                    <sb:title>
                                       <sb:maintitle>Latin America</sb:maintitle>
                                    </sb:title>
                                    <sb:volume-nr>15</sb:volume-nr>
                                 </sb:series>
                              </sb:book-series>
                              <sb:date>2021</sb:date>
                              <sb:publisher>
                                 <sb:name>Curr Fungal Infect Rep</sb:name>
                              </sb:publisher>
                           </sb:book>
                           <sb:pages>
                              <sb:first-page>93</sb:first-page>
                              <sb:last-page>103</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0012">Macedo D., Leonardelli F., Gamarra S., Garcia-Effron G. Emergence of triazole resistance in Aspergillus spp. in Latin America. Curr Fungal Infect Rep. 2021;15:93–103.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0013">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0013">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Alvarez-Moreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Lavergne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hagen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Morio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Meis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Le Pape</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Azole-resistant Aspergillus fumigatus harboring TR(34)/L98H, TR(46)/Y121F/T289A and TR(53) mutations related to flower fields in Colombia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci Rep</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45631</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0013">Alvarez-Moreno C., Lavergne R.A., Hagen F., Morio F., Meis J.F., Le Pape P. Azole-resistant Aspergillus fumigatus harboring TR(34)/L98H, TR(46)/Y121F/T289A and TR(53) mutations related to flower fields in Colombia. Sci Rep. 2017;7:45631.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0014">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0014">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO fungal priority pathogens list to guide research</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development and Public Health Action</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2022</sb:date>
                              <sb:publisher>
                                 <sb:name>Geneva: World Health Organization</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Licence: CC BY-NC-SA 3.0 IGO</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srctxt0014">WHO fungal priority pathogens list to guide research, Development and Public Health Action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Cole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Govender</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chakrabarti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sacarlal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Denning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improvement of fungal disease identification and management: combined health systems and public health approaches</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e412</sb:first-page>
                              <sb:last-page>e419</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0015">Cole D.C., Govender N.P., Chakrabarti A., Sacarlal J., Denning D.W. Improvement of fungal disease identification and management: combined health systems and public health approaches. Lancet Infect Dis. 2017;17:e412–9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0016">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0016">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Falci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Pasqualotto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical mycology in Latin America and the Caribbean: a snapshot of diagnostic and therapeutic capabilities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mycoses</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>368</sb:first-page>
                              <sb:last-page>373</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0016">Falci D.R., Pasqualotto A.C. Clinical mycology in Latin America and the Caribbean: a snapshot of diagnostic and therapeutic capabilities. Mycoses. 2019;62:368–73.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0017">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0017">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ortiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Varela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Fontecha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Torres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Cornely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Salmanton-García</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strengthening fungal infection diagnosis and treatment: an In-depth analysis of capabilities in Honduras</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Open Forum Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2024</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>ofae578</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0017">Ortiz B., Varela D., Fontecha G., Torres K., Cornely O.A., Salmanton-García J. Strengthening fungal infection diagnosis and treatment: an In-depth analysis of capabilities in Honduras. Open Forum Infect Dis. 2024;11:ofae578.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0018">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0018">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>San Juan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Fernández</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Almaguer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Perurena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Martínez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Velar</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Sensibilidad in vitro de cepas cubanas de Aspergillus spp. De origen clínico y ambiental</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomédica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>452</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0018">San Juan J.L., Fernández C.M., Almaguer M., Perurena M., Martínez G., Velar R., et al. Sensibilidad in vitro de cepas cubanas de Aspergillus spp. De origen clínico y ambiental. Biomédica. 2017;37:452–9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0019">
                     <ce:label>19</ce:label>
                     <ce:other-ref id="sbref0019">
                        <ce:textref>Hospital Universitario Nacional de Colombia. Estándares Clínicos Basados en Evidencia 2021 [Available from: <ce:inter-ref id="interref0002" xlink:href="https://www.hun.edu.co/estandares-clinicos-basados-en-la-evidencia-hun" xlink:type="simple">https://www.hun.edu.co/estandares-clinicos-basados-en-la-evidencia-hun</ce:inter-ref>.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Ministerio de Salud y Protección Social</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Guía Metodológica Para La Elaboración De Guías de Práctica Clínica Con Evaluación Económica En El Sistema General De Seguridad Social En Salud Colombiano</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2014</sb:date>
                              <sb:publisher>
                                 <sb:name>Bogotá. Colombia</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0020">Ministerio de Salud y Protección Social. Guía Metodológica Para La Elaboración De Guías de Práctica Clínica Con Evaluación Económica En El Sistema General De Seguridad Social En Salud Colombiano. Bogotá. Colombia; 2014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0021">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0021">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Ministerio de Salud y Protección Social</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Guía Metodológica, Adopción Adaptación De Guías de Práctica Clínica Basadas en Evidencia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2017</sb:date>
                              <sb:publisher>
                                 <sb:name>Guía metodológica en Internet. Edición 1ª. Bogotá DC</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                        <sb:comment>Disponible en gpc.minsalud.gov.co</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srctxt0021">Ministerio de Salud y Protección Social. Guía Metodológica, Adopción Adaptación De Guías de Práctica Clínica Basadas en Evidencia. Guía metodológica en Internet. Edición 1ª. Bogotá DC. 2017, Disponible en gpc.minsalud.gov.co.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0022">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0022">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Brouwers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Kho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.P.</ce:given-name>
                                 <ce:surname>Browman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Burgers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cluzeau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Feder</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AGREE II: advancing guideline development, reporting and evaluation in health care</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>CMAJ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>182</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>E839</sb:first-page>
                              <sb:last-page>E842</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0022">Brouwers M.C., Kho M.E., Browman G.P., Burgers J.S., Cluzeau F., Feder G., et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839–42.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0023">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0023">
                        <sb:comment>3rd</sb:comment>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.F.</ce:given-name>
                                 <ce:surname>Patterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Denning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Fishman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hadley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Herbrecht</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e1</sb:first-page>
                              <sb:last-page>e60</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0023">Patterson T.F., Thompson G.R., 3rd, Denning D.W., Fishman J.A., Hadley S., Herbrecht R., et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–e60.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0024">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0024">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Teh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Yeoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Haeusler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Yannakou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fleming</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lindsay</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Intern Med J</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 7</sb:issue-nr>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>67</sb:first-page>
                              <sb:last-page>88</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0024">Teh B.W., Yeoh D.K., Haeusler G.M., Yannakou C.K., Fleming S., Lindsay J., et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Intern Med J. 2021;51 Suppl 7:67–88.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Douglas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.C.</ce:given-name>
                                 <ce:surname>Smibert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bajel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Halliday</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Lavee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>McMullan</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Intern Med J</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 7</sb:issue-nr>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>143</sb:first-page>
                              <sb:last-page>176</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0025">Douglas A.P., Smibert O.C., Bajel A., Halliday C.L., Lavee O., McMullan B., et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51 Suppl 7:143–76.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0026">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0026">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Oñate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rivas-Pinedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Saavedra-Trujillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Camacho-Moreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Enciso-Olivera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Cuervo-Maldonado</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Section 2. Colombian consensus for prophylaxis, treatment and prevention of invasive aspergillosis in adult and pediatric patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Infectio</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2022</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>297</sb:first-page>
                              <sb:last-page>339</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0026">Oñate J.M., Rivas-Pinedo P., Saavedra-Trujillo C.H., Camacho-Moreno G., Enciso-Olivera L., Cuervo-Maldonado S.I., et al. Section 2. Colombian consensus for prophylaxis, treatment and prevention of invasive aspergillosis in adult and pediatric patients. Infectio. 2022;26:297–339.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0027">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0027">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Gutierrez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Pulido Álvarez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>de la Hoz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Alviar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Ó.M.</ce:given-name>
                                 <ce:surname>Muñoz Velandia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Guerrero Carvajar</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Guía Metodológica Para La Elaboración De Guías de Práctica Clínica Con Evaluación Económica En El Sistema General De Seguridad Social En Salud Colombiano Bogotá DC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2014</sb:date>
                              <sb:publisher>
                                 <sb:name>Fundación Santa Fe de Bogotá - Centro de Estudios e Investigación en Salud</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0027">Gutierrez G.C., Pulido Álvarez A.C., de la Hoz A.M., Alviar K.M., Muñoz Velandia Ó.M., Guerrero Carvajar R., et al. Guía Metodológica Para La Elaboración De Guías de Práctica Clínica Con Evaluación Económica En El Sistema General De Seguridad Social En Salud Colombiano Bogotá DC: Fundación Santa Fe de Bogotá - Centro de Estudios e Investigación en Salud; 2014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0028">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0028">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Andrews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Guyatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Oxman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Alderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dahm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Falck-Ytter</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Clin Epidemiol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>719</sb:first-page>
                              <sb:last-page>725</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0028">Andrews J., Guyatt G., Oxman A.D., Alderson P., Dahm P., Falck-Ytter Y., et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66:719–25.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0029">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0029">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pedraza-Sánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E</ce:given-name>
                                 <ce:surname>González-Jaramillo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Metodología de investigación y lectura crítica de estudios: metodología de calificación y resumen de las opiniones dentro de consensos formales</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rev Colomb Psiquiatr</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>777</sb:first-page>
                              <sb:last-page>785</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0029">Pedraza-Sánchez R., González-Jaramillo L.E. Metodología de investigación y lectura crítica de estudios: metodología de calificación y resumen de las opiniones dentro de consensos formales. Rev Colomb Psiquiatr. 2009;38:777–85.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.N.</ce:given-name>
                                 <ce:surname>Mattiuzzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Estey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Raad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Giles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>450</sb:first-page>
                              <sb:last-page>456</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0030">Mattiuzzi G.N., Estey E., Raad I., Giles F., Cortes J., Shen Y., et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003;97:450–6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0031">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0031">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Westling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.K.</ce:given-name>
                                 <ce:surname>Boge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Zaoutis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Dvorak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nieder</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prospective evaluation of galactomannan and (1‒&gt;3) beta-<ce:small-caps>d</ce:small-caps>-glucan assays as diagnostic tools for invasive fungal disease in children, adolescents, and young adults with acute myeloid leukemia receiving fungal prophylaxis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Pediatric Infect Dis Soc</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>864</sb:first-page>
                              <sb:last-page>871</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/jpids/piab036</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0031">Fisher B.T., Westling T., Boge C.L.K., Zaoutis T.E., Dvorak C.C., Nieder M., et al. Prospective evaluation of galactomannan and (1‒&gt;3) beta-d-glucan assays as diagnostic tools for invasive fungal disease in children, adolescents, and young adults with acute myeloid leukemia receiving fungal prophylaxis. J Pediatric Infect Dis Soc. 2021;10(8):864–71. doi: https://doi.org/10.1093/jpids/piab036.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0032">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0032">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Calmettes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gabriel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Servant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bouchet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kabore</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>42</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>26724</sb:first-page>
                              <sb:last-page>26736</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0032">Calmettes C., Gabriel F., Blanchard E., Servant V., Bouchet S., Kabore N., et al. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. Oncotarget. 2018;9(42):26724–36.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0033">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0033">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Girmenia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Micozzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gentile</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Santilli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Arleo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cardarelli</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Clin Oncol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>667</sb:first-page>
                              <sb:last-page>674</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0033">Girmenia C., Micozzi A., Gentile G., Santilli S., Arleo E., Cardarelli L., et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28:667–74.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0034">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0034">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nucci</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How I treat Febrile Neutropenia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mediterr J Hematol Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:article-number>e2021025</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0034">Nucci M. How I treat Febrile Neutropenia. Mediterr J Hematol Infect Dis. 2021;13:e2021025.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Stanzani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Battista</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sassi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Tolomelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Clissa</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>610</sb:first-page>
                              <sb:last-page>616</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0035">Stanzani M., Battista G., Sassi C., Lewis R.E., Tolomelli G., Clissa C., et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis. 2012;54:610–6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0036">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0036">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Henzler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Henzler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Buchheidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Nance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Weis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Vogelmann</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diagnostic performance of contrast enhanced pulmonary computed tomography angiography for the detection of angioinvasive pulmonary aspergillosis in immunocompromised patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci Rep</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4483</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0036">Henzler C., Henzler T., Buchheidt D., Nance J.W., Weis C.A., Vogelmann R., et al. Diagnostic performance of contrast enhanced pulmonary computed tomography angiography for the detection of angioinvasive pulmonary aspergillosis in immunocompromised patients. Sci Rep. 2017;7:4483.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0037">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0037">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Stanzani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sassi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sartor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rasetto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cavo</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: a pilot study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Infect</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>83</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>371</sb:first-page>
                              <sb:last-page>380</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0037">Stanzani M., Sassi C., Lewis R., Sartor C., Rasetto G., Cavo M., et al. Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: a pilot study. J Infect. 2021;83:371–80.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0038">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0038">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mercier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Castagnola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Marr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Wheat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Verweij</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Maertens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 2</sb:issue-nr>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S89</sb:first-page>
                              <sb:last-page>S94</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0038">Mercier T., Castagnola E., Marr K.A., Wheat L.J., Verweij P.E., Maertens J.A. Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases. Clin Infect Dis. 2021;72 (Suppl 2):S89–S94.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0039">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0039">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.R.</ce:given-name>
                                 <ce:surname>Aquino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Z.</ce:given-name>
                                 <ce:surname>Goldani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Pasqualotto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mycopathologia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>163</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>191</sb:first-page>
                              <sb:last-page>202</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0039">Aquino V.R., Goldani L.Z., Pasqualotto A.C. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia. 2007;163:191–202.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.A.</ce:given-name>
                                 <ce:surname>Du Rand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blaikley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Booton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Chaudhuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Khalid</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Thorax</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 1</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>i1</sb:first-page>
                              <sb:last-page>i44</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0040">Du Rand I.A., Blaikley J., Booton R., Chaudhuri N., Gupta V., Khalid S., et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013;68 Suppl 1:i1–i44.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0041">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0041">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mohan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Madan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Hadda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tiwari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mittal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Guleria</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Guidelines for diagnostic flexible bronchoscopy in adults: joint Indian Chest Society/National College of chest physicians (I)/Indian association for bronchology recommendations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lung India</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Supplement</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S37</sb:first-page>
                              <sb:last-page>S89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0041">Mohan A., Madan K., Hadda V., Tiwari P., Mittal S., Guleria R., et al. Guidelines for diagnostic flexible bronchoscopy in adults: joint Indian Chest Society/National College of chest physicians (I)/Indian association for bronchology recommendations. Lung India. 2019;36(Supplement):S37–S89.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0042">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0042">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Sangoi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Rogers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Longacre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Montoya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Baron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Banaei</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am J Clin Pathol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>364</sb:first-page>
                              <sb:last-page>375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0042">Sangoi A.R., Rogers W.M., Longacre T.A., Montoya J.G., Baron E.J., Banaei N. Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution. Am J Clin Pathol. 2009;131:364–75.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0043">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0043">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Powers-Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Hanson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular diagnostic testing for Aspergillus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Clin Microbiol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2655</sb:first-page>
                              <sb:last-page>2660</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0043">Powers-Fletcher M.V., Hanson K.E. Molecular diagnostic testing for Aspergillus. J Clin Microbiol. 2016;54:2655–60.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0044">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0044">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Kidd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Halliday</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A new age in molecular diagnostics for invasive fungal disease: are we ready?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front Microbiol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2903</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0044">Kidd S.E., Chen S.C., Meyer W., Halliday C.L. A new age in molecular diagnostics for invasive fungal disease: are we ready? Front Microbiol. 2019;10:2903.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Arvanitis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Anagnostou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Fuchs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Caliendo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mylonakis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular and nonmolecular diagnostic methods for invasive fungal infections</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin Microbiol Rev</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>490</sb:first-page>
                              <sb:last-page>526</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0045">Arvanitis M., Anagnostou T., Fuchs B.B., Caliendo A.M., Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27:490–526.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0046">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0046">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Chau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Daveson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Alffenaar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gwee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.E.</ce:given-name>
                                 <ce:surname>Marriott</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Intern Med J</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 7</sb:issue-nr>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37</sb:first-page>
                              <sb:last-page>66</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0046">Chau M.M., Daveson K., Alffenaar J.C., Gwee A., Ho S.A., Marriott D.J.E., et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Intern Med J. 2021;51 Suppl 7:37–66.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0047">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0047">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Personett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Kayhart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Barreto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tosh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dierkhising</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mara</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Renal recovery following liposomal amphotericin B-induced nephrotoxicity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Nephrol</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>8629891</sb:article-number>
                        </sb:host>
                        <sb:comment>2019</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srctxt0047">Personett H.A., Kayhart B.M., Barreto E.F., Tosh P., Dierkhising R., Mara K., et al. Renal recovery following liposomal amphotericin B-induced nephrotoxicity. Int J Nephrol. 2019;2019:8629891.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0048">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0048">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Alvarez-Lerma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rodriguez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Soriano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Catalan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Llorente</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Vidart</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rev Esp Quimioter</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>360</sb:first-page>
                              <sb:last-page>368</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0048">Alvarez-Lerma F., Rodriguez M., Soriano M.C., Catalan M., Llorente A.M., Vidart N., et al. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy. Rev Esp Quimioter. 2013;26:360–8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0049">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0049">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Obata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takazono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tashiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wakamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin Exp Nephrol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>279</sb:first-page>
                              <sb:last-page>287</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0049">Obata Y., Takazono T., Tashiro M., Ota Y., Wakamura T., Takahashi A., et al. The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study. Clin Exp Nephrol. 2021;25:279–87.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.I.</ce:given-name>
                                 <ce:surname>Raad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Zakhem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Helou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Kontoyiannis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hachem</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Antimicrob Agents</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>283</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0050">Raad, I.I., Zakhem A.E., Helou G.E., Jiang Y., Kontoyiannis D.P., Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45:283–8.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0051">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0051">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Aruanno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Glampedakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lamoth</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Antimicrob Agents Chemother</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e00399-19</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srctxt0051">Aruanno M., Glampedakis E., Lamoth F. Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside. Antimicrob Agents Chemother. 2019;63:e00399-19.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0052">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0052">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Azanza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mensa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Barberan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Vazquez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Perez de Oteyza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recommendations on the use of azole antifungals in hematology-oncology patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rev Esp Quimioter</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2023</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>236</sb:first-page>
                              <sb:last-page>258</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0052">Azanza J.R., Mensa J., Barberan J., Vazquez L., Perez de Oteyza J., Kwon M., et al. Recommendations on the use of azole antifungals in hematology-oncology patients. Rev Esp Quimioter. 2023;36:236–58.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0053">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0053">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Ashbee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Barnes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Richardson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gorton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Hope</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Antimicrob Chemother</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1162</sb:first-page>
                              <sb:last-page>1176</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srctxt0053">Ashbee H.R., Barnes R.A., Johnson E.M., Richardson M.D., Gorton R., Hope W.W. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162–76.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>